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ABSTRACT

THE EFFECT OF ZINC ON SKELETAL ALKALINE PHOSPHATASE AND ON
SKELETAL TISSUE
by
Susan L. Hall

Zinc is essential for normal growth, however, very little is known about the mechanisms
by which zinc influences growth. ALP, an ectoenzyme expressed in high levels in
osteoblasts, is a zinc-containing metalloenzyme and is important in bone formation.
Preliminary studies showed that low levels of zinc could increase ALP specific activity in
human osteosarcoma, SaOS-2 cells. Current studies were designed to characterize this
zinc effect, test possible mechanisms, and determine whether the effect is physiologically
relevant. Incubation with zinc resulted in a time and dose dependent increase in ALP
specific activity in the extracts and conditioned media of SaOS-2 cells, and prevented the
loss of ALP activity which results from phosphate withdrawal. Divalent cations other
than zinc were unable to increase ALP activity, suggesting this action is unique to zinc.
Normal human bone cells and MG-63 cells showed zinc-dependent increases in ALP
activity similar to that observed in SaOS-2 cells. The effect of zinc was not associated
with changes in protein synthesis, collagen production, ALP mRNA levels, enzyme
release or ALP immunoreactive protein level. Zinc had a biphasic dose-dependent effect

phosphatase activity and a small negative effect on IGF-II synthesis. Following
phosphate withdrawal, some of the ALP activity loss was reversible by zinc and part was
irreversible (i.e. required new protein synthesis). Zinc increased the half-life of ALP
activity in intact cells and in purified and crude ALP enzyme preparations, suggesting
that zinc has a direct effect on enzyme stability. Phosphate was able to inhibit the zinc
chelating action of EDTA and prevent the inhibition of ALP activity. The effect of zinc
to increase ALP activity was not dependent on free ionic zinc, but also occurred with
albumin-bound zinc. Dietary zinc intake was positively associated with ALP activity in
serum and in tibial bone of adult female mice, suggesting the zinc effect may be
physiologically relevant. We conclude that zinc increases ALP activity by acting directly
on the enzyme, probably by stabilizing it and we hypothesize that differential zinc
dissociation from the ALP active center may explain our results.
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INTRODUCTION
A. ZINC

Zinc is an essential trace element present in all organs, tissues, fluids and secretions of
the body. The majority of total body zinc is stored in muscle (57%) and bone (29%)(1)
but these pools do not represent readily available zinc sources. Therefore, the
homeostatic regulation of total body zinc is probably controlled by a balance between
intestinal absorption and excretion from tissue pools into the feces.

Normal adult

human serum contains 40-100 ug/L of zinc, the majority of which is protein-bound.
Serum zinc has been classified as firmly bound (34%) and loosely bound (66%),^
presumably representing metalloenzymes and metal-protein complexes, respectively.
Studies analyzing the interactions between zinc and serum proteins(4) demonstrated that
exogenous zinc could readily bind to albumin, suggesting that exogenous zinc is
transported in the serum by binding to albumin. Metabolic balance studies indicate a
nutritional zinc requirement of 10.1 - 11.5 mg/day.(5) The typical dietary intake has been
estimated to be 10 - 15 mg/day in young adults, and 7-10 mg/day in the elderly.(6)
Several metabolic functions requiring zinc have been identified including binding of
zinc fmger-containing transcription factors, stabilization of ribosomes, RNA, DNA and
some hormone-receptor complexes, regulation of tubulin polymerization, taste and
immune system functioning and wound healing. In addition, zinc has been identified as
an essential cofactor for over 200 enzymes.

(7,8)

1

It appears that zinc can function in these
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metalloenzymes in one of three roles: 1. maintenance of proper enzyme structure
(e.g. the Cu- and Zn-superoxide dismutases), 2. regulation of enzyme activity
(e.g. fructose bisphosphatase) and 3. participation in the catalytic mechanism at the active
site (e.g. carbonic anhydrase and E. coli alkaline phosphatase).(5)
Numerous clinical manifestations have been associated with zinc deficiencies
including growth retardation, hypogonadism and related disorders, alopecia, skin and eye
lesions, immune deficiencies, and impaired taste and appetite. It is believed that most
zinc deficiency occurs under conditions of starvation, and therefore, occurs
simultaneously with deficiencies of several nutrients. The lack of several nutritional
requirements occurring in the same subject at the same time makes the assignment of
specific symptoms to a specific nutrient very difficult, if not impossible. The
determination of the clinical symptoms of zinc deficiency in humans did not occur until
the 1960’s when several studies were done which examined the clinical manifestations of
zinc deficiency in Egyptian and Iranian patients. In some parts of the Middle East, the
diet consists mainly of bread with a low intake of animal protein. This type of diet is
deficient in iron and zinc, but generally is not deficient in other nutrients and therefore,
presented the opportunity to distinguish symptoms attributable to iron and zinc
deficiencies from each other and from symptoms of other nutrient deficiencies. In the
first of these reports, clinical signs of stunted growth and hypogonadism in a group of
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patients were improved with zinc supplementation.(9) Subsequent studies have given
conflicting results with some reports (10,11) demonstrating positive associations between
zinc and improvements in bone growth and sexual development in Middle Eastern
adolescents and another report showing no such associations/1^ In preschool children in
Turkey, height velocity was increased in zinc supplemented subjects compared to
control subjects.(13) Zinc deficiency may also be associated with postmenopausal
osteoporosis, in as much as, one report, measuring serum zinc levels, estimated that
thirty-nine percent of all women over 65 years of age were zinc deficient.

(14)

Numerous studies have examined the effects of zinc deficiency using animal models.
As in the clinical studies in the Middle East, growth retardation and testicular atrophy
were observed in zinc deficient rats, (15,16) pigs,(17) lambs,(18) calves,(19) and dogs. (20) In
addition, several studies have characterized the effect of zinc deficiency in the fetal rat
system and have reported prominent skeletal malformations and calcification
defects.(2123) It has been suggested that zinc deficiency may impair the growth of young
humans and animals by reducing cell division.(5) Abnormal bone growth and maturity
may result from the reduction in cell proliferation. Zinc deficiency can decrease the
number of osteoblasts and chondrocytes in epiphyseal cartilage/241 Furthermore, high
concentrations of zinc have been localized to the hypertrophic zone of epiphyseal
cartilage.

(25,26)

These data suggest that zinc may play a role in bone formation.
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Numerous studies have been conducted to test the effect of zinc on various parameters
of bone formation and bone resorption. Investigations of the effect of zinc on the DNA
content of the bones of weanling rats have reported conflicting results. Zinc-dependent
increases in DNA content were observed in the femoral tissue(27 28) and in calvarial organ
cultures(29) of weanling rats and in the mouse osteoblastic cell line, MC3T3-E1 .(30) In
contrast, in another study using the weanling rat calvaria model, no effect of zinc on
DNA content was observed.(31)
Zinc also inhibits bone resorption, in vitro, by reducing the number of resorption pits
observed in a culture of rat osteoclasts, without a proportional reduction in osteoclast
number.(32) This effect may reflect an action of zinc on transforming growth factor-p
(TGF-p). TGF-P appears to have a biphasic effect on osteoclasts in mouse marrow
cultures with low doses of TGF-p stimulating the formation of osteoclast-like cells and
high doses inhibiting the process. Zinc inhibits the low-dose stimulatory effect of TGF-p
on osteoclast-like cell formation/33^ In contrast to these findings, acid phosphatase, an
enzyme found in abundance in osteoclasts and which is believed to play a role in bone
resorption, is increased in the bones of young rats treated with zinc supplemented
diets.(28) These increases in acid phosphatase activity were not observed, however, in
another study which assessed acid phosphatase activity in extracts of rat
calvaria organ cultures incubated with zinc.(31) Further studies will be required to
delineate these presumptive actions of zinc on osteoclastic bone resorption.
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Zinc has also been shown to affect osteoblastic function, both in vivo and in vitro. The
collagen content of femoral tissue was increased in weanling rats on zinc supplemented
diets(27) and collagen production was increased in rat calvaria bones incubated in media
containing zinc. (27,31)
The calcium content of rat femoral diaphyses was increased by dietary administration
of zinc(27) and of a zinc-containing compound,(34) suggesting that zinc may be involved in
the process of mineralization. Furthermore, several studies have shown the positive
effects of zinc on alkaline phosphatase (ALP) activity. Although the precise
physiological function of ALP in bone tissues is unknown, it has been suggested that the
enzyme may play a role in bone mineralization.

(35-37)

Dietary zinc supplementation has

been associated with an increase in ALP activity in the femoral diaphysis,

(27,28)

and in

calvarial bone organ cultures(31) of weanling rats. Furthermore, the observed increase in
ALP activity in the femoral diaphyses, was shown to be unique to zinc, in that dietary
supplementation with copper, magnesium, cobalt, nickel, and chromium III caused
significant decreases in the ALP activity of the femoral tissues. In another study using
weanling rats, zinc deficiency was associated with decreases in the ALP activity of
homogenized bone tissues. In addition, dietary repletion with zinc resulted in increases in
ALP activity.(38) In the young rat femoral model, zinc prevents the loss of ALP activity
which occurs with skeletal unloading,

(39-41)

and enhances the effect of

la,25-dihydroxyvitamin D3 to increase ALP activity.

(42)

6

Protein synthesis has also been reported to be increased by the addition of zinc to bone
cultures of rat calvaria

(29,43)

and to cultures of mouse-derived MC3T3-E1 cells. (30)

Cycloheximide, a protein synthesis inhibitor, blocks many of the effects of zinc on bone
metabolism. In the rat studies described above, low doses of cycloheximide were shown
to block the zinc-dependent increases in alkaline phosphatase activity(28) and collagen
content^3in the femoral diaphyses and calvaria organ cultures, respectively.
Furthermore, inhibition of protein synthesis with the use of cycloheximide abolished the
effects of zinc to restore ALP activity in the femoral tissues of rats subjected to skeletal
unloading(41) and to enhance the effect of la,25-dihydroxyvitamin D3 on ALP
activity/42^ And finally, in the MC3T3-E1 study, incubation with cycloheximide
prevented the previously observed increases in protein and DNA content.

(30)

The

possibility that the observed changes in protein synthesis of bones incubated with zinc
could be due to changes in RNA levels was investigated in the rat calvaria model.
However, no changes in RNA synthesis, as measured by the incorporation of
[14C]-uridine incorporation, were observed.(43) The variety of effects of zinc on bone
tissues described in these reports suggests that zinc may act by several differ mechanisms
to influence bone metabolism. In the studies summarized in this report, we have focused
our attention on one specific aspect of the skeletal effects of zinc; the observed effect of
zinc to modulate the level of skeletal ALP activity in mammalian osteoblast-line cells.

7

Although zinc appears to be essential for several biological functions, an excess of
zinc can be toxic. Zinc toxicity has been reported at doses exceeding the Recommended
Daily Allowance by ten- to twenty-fold, and acute toxicity has been observed at 5Ox the
RDA (i.e. a dose of 2g).(5)

ALKALINE PHOSPHATASE (ALP)
Skeletal alkaline phosphatase is a membrane-bound ectoenzyme expressed by
osteoblasts. Skeletal ALP is anchored to the outer plasma membrane by a proteoglycan
inositol linkage to phosphatidylinositol,(44) and can be released by a glycan-inositol
hydrolase and/or by membrane vesicle formation. Although the precise physiological
function of sALP is unknown, it appears that the enzyme is essential for bone formation
and ALP is commonly used as a marker for osteoblast differentiation. Skeletal ALP
activity in serum is also interpreted as an index of the rate of bone formation.

(45-50)

The

importance of skeletal ALP in the bone formation process is suggested by three
observations: mineralization capability is induced in ALP-negative cells following
transfection with ALP cDNA,(35) cartilage calcification was inhibited following
sterospecific inhibition of ALP activity in vitro,^ and a lethal form of hypophosphatasia
has been associated with a missense mutation in the human sALP gene.

(37)

Previous

studies have suggested several possible roles for skeletal alkaline phosphatase in bone
mineralization. In 1924, it was proposed that the phosphate produced by the action of
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ALP on phosphoester substrates, may precipitate with calcium, facilitating
mineralization/5It has also been proposed that ALP may hydrolyze an inhibitor of bone
mineralization, such as inorganic pyrophosphate/52) In addition, it has been suggested
that ALP may participate in mineralization by binding calcium, which would serve as a
nucleus for calcium phosphate crystallization.(53) Other hypotheses suggest that as an
ectoenzyme, ALP may regulate the entry of metabolites into the cell by
dephosphorylation, or that the enzyme may act as a receptor.(54) Alternatively, since
tissue-nonspecific ALP has been shown to bind to matrix proteins such as collagen,(55) it
has been proposed that ALP may promote calcification by attaching osteoblasts to the
matrix.(54) Finally, it has been suggested that skeletal ALP may be involved in the
transport of calcium into osteoblasts.

(56, 57)

ALP is a zinc-containing metalloenzyme which may account for the observed effects
of zinc on ALP activity. Previous studies of ALP activity have shown that removing the
metal ions with chelating agents caused significant inactivation of ALP activity. This
inactivation is reversible in the E. coli ALP, but irreversible for the mammalian ALP
enzymes.
The majority of the work investigating the role of zinc in the catalytic action of ALP
has been done on the ALP enzyme of E. coli. The E. coli ALP enzyme has been shown
to be a nonspecific phosphoesterase, which catalyzes the hydrolysis of
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phosphoryl-monoesters and diesters, and of related phosphoryl derivatives. (58) Four
moles of zinc and two moles of magnesium have been found to be associated with the
80,000 MW ALP dimer(59) suggesting that each catalytic subunit contains two zinc atoms
and one magnesium atom. Figure 1 depicts an illustration of the proposed structure of the
E. coli ALP active site showing the coordination of one zinc atom (Zn), a second zinc
atom (Zn*) and a magnesium atom (Mg).(58) As a IIB element with two electrons located
in the s electron subshell, zinc usually forms tetrahedral complexes with ligands (i.e. zinc
has a coordination number of 4), however complexes with 5 and 6 ligands have also been
observed.(5) In the ALP active site of E. coli, the one zinc atom (Zn) is coordinated to the
two carboxylate oxygens of the side chain of aspartate-327 and to the imidazole nitrogens
of histidine-331 and histidine-412. One to two water molecules are also probably weakly
associated with this zinc atom. The second zinc atom (Zn*) is coordinated to the
hydroxyl group of serine-102, to the imidazole nitrogen of histidine-370, to one
carboxylate oxygen of aspartate-51 and to one carboxylate oxygen of aspartate-369. The
magnesium atom is bridged to the Zn* atom via aspartate-51 (one oxygen of the carboxyl
side chain being attached to the two metals), and also interacts with the hydroxyl group of
threonine-155 and with one of the oxygens of glutamate-322.
The hypothesized catalytic mechanism of action of the E. coli ALP enzyme has been
described in detail elsewhere.(60) Briefly, this catalysis is thought to occur in two steps,
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Figure 1. Illustration of the E. coli ALP Active Site. The ALP active site contains two
zinc atoms and one magnesium atom. One zinc atom is coordinated to the two
carboxylate oxygens of the side chains of an aspartate residue (D), to the imidazole
nitrogens of two histidine residues (H) and to at least one water molecule (H20). The
second zinc atom (Zn*) is coordinated to the hydroxyl group of a serine residue (S), to
one of the carboxylate oxygens of two aspartate residues and to the imidazole nitrogen of
a histidine residue. Reprinted from Vallee BL and Auld DS, New Perspective on Zinc
Biochemistry: Cocatalytic Sites in Multi-zinc Enzymes. Biochemistry, Volume 32,
Number 26: 6493-6500, 1993.

1—I
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with two of the ionic oxygens in the phosphate group of the monoester or diester
substrate interacting with the two zinc atoms. Figure 2 shows the overall reaction of ALP
with a phosphoester substrate.

In the first step, the Zn* atom of the enzyme (E)

polarizes a nucleophile (presumably the hydroxyl group of serine-102),(61) which then
attacks one of the phosphoester or amide bonds of the substrate (R-OPi) forming an
enzyme-substrate complex (E-Pi-OR). The other zinc atom (Zn) then acts as a transient
receptor for the alcohol (RO’) or amine leaving group. This results in the formation of an
enzyme-product complex (E-Pi). In the second step of catalysis the roles of the two zinc
atoms are reversed. The Zn atom of the enzyme polarizes a water molecule (H20), which
under alkaline conditions, acts as a nucleophile. The nucleophilic water molecule attacks
the phosphoseryl ester bond between the substrate and serine-102 and replaces the serine
hydroxyl group with the serine leaving group being transferred to the Zn* atom. The
dissociation of the product (Pi) from the enzyme is believed to be the rate limiting step of
the reaction. Although the catalytic mechanism of mammalian skeletal ALP enzyme is
not so clearly understood, the isoenzyme is known to have a similar content of divalent
metal ions (i.e. two molecules of zinc per subunit).

SaOS-2 CELLS
We selected the human osteosarcoma-derived cell line, SaOS-2, as a model system for
our investigations of the in vitro effects of zinc on ALP activity because these cells are

u>

Figure 2. The Overall Reaction of ALP with a Phosphoester Substrate. In the first step, the ALP enzyme (E) reacts with
the phosphoester substrate (R-OPi) to form an enzyme-substrate complex (E-Pi-OR). Nucleophilic attack on the ester bond by
a serine residue of the ALP enzyme results in the transfer of the phosphate to the enzyme and the release of an alcohol (RO ).
In the second (and rate-limiting step), a nucleophilic water molecule (H20) attacks the enzyme-phosphate complex (E-Pi)
resulting in dissociation of the enzyme and the phosphate product (Pi).
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osteoblastic in nature and because they have high expression of ALP activity.
Furthermore, the ALP activity of these cells is indistinguishable from the activity of the
human skeletal ALP enzyme. j Studies in our laboratory comparing subpopulations of
SaOS-2 cells expressing high vs low steady state levels of ALP activity, showed that
subpopulations with higher levels of ALP activity had proportionally higher levels of
collagen synthesis and PTH-dependent cAMP production and proportionally lower levels
of fluoride-sensitive acid phosphatase activity.

(57)

Additionally, we have observed that

phosphate and phosphate-ester analogues can regulate the level of skeletal ALP activity
in SaOS-2 cells. (63) Increasing phosphate concentrations in the culture media increased
the cellular level of ALP activity, whereas, reduction of phosphate concentrations
resulted in a lower level of ALP activity. These results could not be attributed to changes
in transcription levels,

nor to changes in the release of ALP from the cell

membrane.(65) Furthermore, the level of total cellular ALP immunoreactive protein was
not affected by changes in phosphate concentrations.

(65)

ZINC AND ALP
Recent data from a group of unrelated studies (designed to investigate the effects of
fluoro-phosphoryl compounds and zinc on skeletal ALP kinetics and on the proliferation
and differentiation of SaOS-2 cells) suggested that low levels of zinc added to the culture
media could increase the level of ALP activity and could abolish the effect of phosphate
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to regulate the level of skeletal ALP activity (unpublished). Although these findings
were consistent with our understanding of the role of Zn as an essential structural element
of skeletal ALP (like the E. coli enzyme, skeletal ALP is believed to be a
Zn-metalloenzyme with 2 molecules of zinc per molecule of enzyme) such direct effects
of zinc on ALP activity in human osteoblast-line cells have not been described in
previous studies.
The current studies were intended to investigate the role and possible mechanisms by
which zinc increases skeletal ALP activity levels and to study the effects of zinc on the
proliferation and differentiation of human osteoblast-like cells, and finally, to determine
if varying zinc concentrations can influence bone formation in vitro and/or in vivo. Since
previous studies have clearly established that sALP activity, in serum and in bone cells,
can serve as an index of the rate of bone formation, we hypothesized that the effect of
zinc to increase the level of sALP activity (e.g. in SaOS-2 cells) might be associated with
a parallel effect on bone formation. This would be consistent with the effects of agents
like fluoride and calcitonin to increase both ALP activity and bone formation.

(66)

Alternately, it is also possible that zinc has a direct effect on ALP activity which is
independent of the (presumptive) role of ALP in bone formation.
The mechanism by which zinc increases ALP could involve increases in the
transcription of the ALP gene or alternatively, could involve postranscriptional
mechanisms. In humans, the liver/bone/kidney isoenzyme gene is located on the distal
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short arm of chromosome l.(67) It is over 50,000 base pairs in length, encompassing
12 exons with a cDNA sequence length of 2553 base pairs.(68^ The promoter of the ALP
gene has been shown to contain elements characteristic of housekeeping genes: an
atypical TATA box, a rich G-C region, and four potential Spl binding sites
(GGGCGG).

(68,69)

Spl is an enhancer which stimulates transcription regulated by the

SV40 promoter. Furthermore, Spl is a zinc-containing protein and contains three zinc
finger motifs. (70) Therefore, it is possible that the effect of zinc to increase ALP activity
is mediated through Spl enhancement of transcription from the ALP gene. It is also
possible that the effect of zinc is mediated at a posttranscriptional level. Recent studies
suggest that ALP mRNA levels are regulated by posttranslational events rather than by
changes in gene transcription. In one study, a construct containing the liver/bone/kidney
ALP promoter sequence linked to a chloramphenicol acetyltransferase (cat) reporter gene
was transfected into SaOS-2 cells (a cell line with high ALP expression) and into Hela
cells (a cell line with low ALP expression). Even though the two cell lines differ in their
ALP expression by several hundred-fold, they transcribe the cat gene at equal rates.
Nuclear run on experiments also showed equal transcription activity in SaOS-2 cells and
Hela cells/7 ]) In a second study, post-transcriptional regulation of ALP expression was
demonstrated in UMR 201 cells, in that, retinoic acid increased ALP expression by
stabilizing newly synthesized ALP mRNA.

(72)

The current studies were proposed to
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deterimine if zinc affected ALP mRNA levels and if this was found to be the case, further
studies would distinguish between transcriptional and posttranscriptional mechanisms.
Previous studies of the effects of zinc on skeletal tissues have been performed in the
clinical setting or in the laboratory using young rats as a model for in vitro and in vivo
studies. To our knowledge, no other studies have been undertaken to characterize the
observed effects of zinc on ALP activity in human osteoblast-like cells. More
importantly, information gained by these studies will increase our present knowledge of
the presumptive role of zinc in bone formation.
In order to investigate the effect of zinc on the ALP activity in human osteoblast-like
cells we proposed to accomplish the three following specific aims: (1) to characterize
the effect of zinc on alkaline phosphatase activity and on bone cell metabolic processes in
the human osteoblast-like osteosarcoma cell line, SaOS-2, and in normal human bone
cells; (2) to determine the mechanism by which zinc affects the level of ALP activity in
human osteoblast-like cells; and (3) to determine whether the observed effects of zinc are
physiologically relevant, by testing the effect of zinc on skeletal ALP activity in the
serum and the bones of adult female mice.

MATERIALS

The following supplies were purchased from Fisher (Pittsburgh, PA): disposable
transfer pipettes, 12 x 75-mm glass borosillicate test tubes, 13 x 100-mm polypropylene
test tubes, G6 glass fiber filter paper, disposable polyethylene scintillation vials, sodium
acetate, sodium azide, acetone, sodium hydroxide, hydrochloric acid, acetic acid, sodium
chloride, sodium phosphate (monobasic), polyethylene glycol 8000,
3-isobutyl-1-methyl-xanthine (IBMX), guanidium thiocynate, 2-propanol, chloroform,
isoamyl alcohol, and glycerol. The following supplies were purchased from Sigma
Chemical Company (St. Louis, MO): magnesium chloride, p-nitrophenylphosphate,
sodium carbonate, fetal calf serum, diethyl pyrocarbonate (DEPC), sodium dodecyl
sulfate (SDS), sodium bicarbonate, L-histidine, L-alanine, L-tryptophan, L-glutamic acid,
L-valine, L-asparagine, L-threonine, L-cysteine, L-glycine, L-proline, triton-XlOO,
zinc dichloride, sodium fluoride, citric acid, n-lauroyl sarcosine sodium salt,
2-mercaptoethanol, herring sperm single stranded DNA, ethylenediaminetetraacetic acid
(EDTA), ficoll, polyvinylpyrrolidone, tannic acid, phospholipase C, and concanavalin A.
The Sepharose CL-60200 gel, AG 501-x8 mixed bead resin, Bio-Gel P-10 gel, Bio-Spin
disposable chromatography columns, and Bradford dye reagent were purchased from
Bio-Rad (Hercules, CA). Tris, ethidium bromide, bromophenol blue, MOPS, methylene
blue, agarose-LE and formamide were purchased from the United States Biochemical
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Corporation (Cleveland, OH). The 100-mm, 24-place multiwell, and 6-place multiwell
cell culture dishes were obtained from Corning, Inc.(Corning, NY). The 96-well
microtiter plates were purchased from Rainin Instrument Company (Emeryville, CA).
Ascorbic acid, aquacide, DNAse-free bovine serum albumin-fraction V (for the northern
analysis hybridizations) were purchased from Cal Biochem (La Jolla, CA). Bovine
serum albumin used for cell cultures and in the IGF-II isolation procedures was
purchased from Fluka (Ronkonkoma, NH). Tandem-R Ostase ImmunoRadioMetric
Assay (two-site IRMA) was purchased from Hybritech (San Diego, CA). Calcium
chloride was purchased from Merck (Rahway, NJ). The Klenow fragment of DNA
polymerase enzyme was obtained from Promega (Madison, WI). Trichloroacetic acid
and cycloheximide were purchased from Aldrich (Milwaukee, WI). Dextran sulfate was
purchased from Pharmacia Biotech (Piscataway, NJ). Zinc sulfate and sodium tartrate
were purchased from the J.T. Baker Chemical Company (Phillipsburg, NJ). Dulbecco’s
modified Eagle’s medium (DMEM) was purchased from Mediatech, Inc. (Herdon, VA).
The NACA Prepac Cartridges were purchased from Gibco (Grand Island, NY). The
cAMP enzymeimmunoassay (EIA) system was obtained from Amersham (Arlington
Heights, IL). Puritan cotton swabs were obtained from Hardwood Products Company
(Guilford, MA). The parathyroid hormone (PTH) was purchased from Transduction
Laboratories, Inc (Lexington, KY). Goat anti-mouse antibody and non-immune mouse
serum were obtained from Scantibodies (San Diego, CA). Anti-IGF-II antibody was
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purchased from Amano (Troy, VA). 32[P]-labeled ATP, 32[P]-CTP, and 125[ I ] were
purchased from Dupont NEN Research Products (Boston, MA). 3[H]-labeled proline
was purchased from ICN Biochemical, Inc. (Irvine, CA). Swiss-Webster female adult
mice and the mouse food (diet TD 85419) were obtained from Harlan Tekland
(Westbury, NY).

METHODS

A. MAINTENANCE OF CELLS IN CULTURE
SaOS-2 cells were maintained in 100-mm diameter dishes in DMEM + 10% Fetal Calf
Serum (FCS), (7-10 mL/dish) at 37 °C in an atmosphere of 5% C02 and air in a
humidified incubator (VRW Scientific C02 Incubator, Model 2300). For most of our
studies of ALP activity, subconfluent, replicate cultures (n=6/group) were prepared in
24-place multiwell dishes (50,000 - 75,000 cells/mL medium, 1 mL/well). The medium
was replaced 24-48 hours later with 0.5 mL serum-free DMEM and 2-5 hours after that,
with 0.5 mL of the effector medium. Additional studies were also conducted using
subconfluent cultures (n = 6/group) in 6-place multiwell dishes, with an initial plating
density of 500,000 - 750,000 cells/well in 2 mL of DMEM + 10% FCS). The medium
was replaced 24 - 48 hours later with 1.5 mL serum-free DMEM and 2-5 hours after that,
with 1.5 mL of the effector medium. All exposures to effectors were in BGJb medium
with phosphate (Pi) and effector concentrations (e.g. zinc) as indicated. (Note: FittonJackson modified BGJb medium was prepared without calcium or phosphate so that these
components could be added as desired. DMEM normally contains 1.2 mmol/L Pi and
Fitton-Jackson modified BGJb normally contains 1.8 mmol/L Pi. Both formulations
normally contain 1.8 mmol/L calcium.) SaOS-2 cells with very high steady state levels
of ALP activity (1 U/mg protein) were used for all experiments unless otherwise noted.
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B. MEASUREMENT OF ENZYME ACTIVITIES

1. MEASUREMENT OF ALP ACTIVITY IN CELL EXTRACTS AND
CELL-CONDITIONED MEDIA
After 24-48 hours of exposure to serum-free BGJb containing phosphate, zinc and/or
effectors as desired, the cell-conditioned media were removed (and saved) and the cell
layers were rinsed once with phosphate buffered solution (PBS), then scraped and
homogenized (by agitation with a disposable transfer pipette) and extracted with 0.3 mL
of 0.01% triton X-100 (vol/vol). ALP activity was measured in aliquots of these extracts
by hydrolysis of 10 mmol/L p-nitrophenlyphosphate (PNPP) in 0.1 mol/L C03 buffer,
pH 10.3, containing 1 mmol/L MgCl2.

(57, 62, 66, 73)

The same reaction mixture was also

used for measurement of ALP activities in aliquots of cell-conditioned media after
centrifugation (10 minutes at 1500 x g) to remove non-attached cells and broken cells
from the soluble and vesicular ALP activity in the medium. Reaction volumes were
contained in microtiter wells (0.3 mL/well), and p-nitrophenolate production was
measured as the time-dependent increase in optical density at 410 nm using an automated
microtiter plate spectrophotometer (SET Laboratories, Austria). ALP activities were
measured in duplicate, and average values were used for calculations of specific activity,
U/mg protein, where 1 U ALP activity = 1 pmol product (p-nitrophenolate) formed per
minute at 22°C.
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2. MEASUREMENT OF ACID PHOSPHATASE ACTIVITIES
Replicate cultures of SaOS-2 cells were plated in 6-place multiwell dishes
(n = 6/group) at 500,000 to 750,000 cells per well in 2 mL of DMEM media containing
10% FCS. Following overnight incubation, the media was changed to 2 mL serum-free
DMEM, and then changed again to phosphate-free BGJb media with one of 7 doses of
zinc, ranging from 0 to 20 pmol/L. After 48 hours of incubation with zinc, the plates
were rinsed 1 x with PBS solution and stored at -20°C until assay. One and one half mL
of 0.01% Triton X-100 was used to extract the cell layers and aliquots of these extracts
were assayed for total acid phosphatase (AcP), tartrate-resistant AcP (TRAP), and
fluoride sensitive AcP activities, using visible light spectroscopy. To determine total acid
phosphatase levels in the extracts, aliquots of the triton extract (25 pL) were diluted with
75 pL of water and then were incubated with 100 pL of the following reaction mixture:
100 mmol/L sodium acetate, pH 5.5, and 10 mmol/L p-nitrophenylphosphate (PNPP). To
determine the amount of tartrate-resistant acid phosphatase (TRAP) activity of the
extracts, the samples were diluted 1/4 in water, as before, and incubated with 100 pL of
the same reaction mixture containing 80 mmol/L sodium tartrate. The fluoride-sensitive
acid phosphatase activity was assessed by incubation in 100 pL of a reaction mixture
containing 2 mmol/L sodium fluoride. After 90 minutes of incubation at 37°C, each of
these reactions was stopped by the addition of 100 pL of 0.2 N NaOH. Reaction
volumes were contained in microtiter wells (0.3 mL/well, final volume after addition of
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the NaOH), and p-nitrophenolate production was measured as the time-dependent
increase in optical density at 410 nm using an automated microtiter plate
spectrophotometer (SLT Laboratories, Austria). Enzyme activities were measured in
duplicate, and average values were used for calculations of specific activity, mU/mg
protein, where 1 mil AcP activity = 1 nmol product (p-nitrophenolate) formed per minute
at 37°C. The level of fluoride-sensitive acid phosphatase activity was calculated by
subtracting the fluoride-resistant activity (measured in the wells containing
2 mmol/L sodium fluoride) from the total AcP activity.

C) MEASUREMENT OF PROTEIN CONCENTRATION

1. MEASUREMENT OF CELL LAYER PROTEIN
Protein concentrations of cell layer extracts were determined by the dye binding method
of Bradford.(74) Since triton X-100 is known to interfere with this assay’s measurements,
cells were extracted at a very low triton concentration (0.01%) and all blanks and protein
standards were also prepared in 0.01% triton X-100.

2. MEASUREMENT OF 3[H]-PROLINE INCORPORATION
The incorporation of 3 [H]-proline into trichloroacetic acid-precipitated material was
measured in replicate cultures of SaOS-2 cells (m=6, in 24-place multiwell dishes) as an
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index of the rate of protein synthesis in response to zinc, in the absence of phosphate.
Following a 4 hour serum-free preincubation, the cells were incubated for 48 hours in
phosphate-free BGJb containing 0.1% of the normal proline concentration of BGJb
3

medium at zinc concentrations ranging from 0 to 20 pmol/L. Two pCi of [H]-proline
was added to the treatment media for the final 16 hours of the incubation. The
incorporation of the radioactive amino acid into newly synthesized proteins was
determined by precipitating proteins onto cotton swabs in the presence of
12.5% trichloroacetic acid (TCA). To remove unincorporated 3 [H]-proline, the cotton
swabs were rinsed once in 12.5% TCA for 15 minutes, and to remove the TCA, the swabs
were rinsed once in ethanol for 15 minutes. The swabs were then assayed for
radioactivity and the data are reported here as counts per minute/culture well (cpm/well).

3. MEASUREMENT OF ALP IMMUNOREACTIVE PROTEIN
The amount of skeletal ALP immunoreactive protein was quantitated in aliquots of
cell layer extracts (solutions of 0.01% triton X-100 in a buffer containing
12.5 mmol/L NaHC03, 12.5 mmol/liter Tris and 0.01% sodium azide, at pH 7.0) and in
aliquots of cell-conditioned media by a two-site immunoradiometric assay, using a
commercial kit (Hybritech) according to manufacturer’s instructions. Although the
standards were measured in duplicate, single determinations were made for each of the
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replicate cell extracts and samples of conditioned culture medium. All measurements
were within the linear range of the standard curve.

D. OSTEOBLAST ACTIVITY ASSAYS

1. COLLAGENASE DIGESTIBLE PROTEIN
To assess the effect of zinc on the production of collagen, SaOS-2 cells were plated in
6-place multiwell plates in 2 mL DMEM + 10% PCS, with an initial cell density ranging
from 500,000 - 750,000 cells per well. Following overnight incubation, and a two-hour
serum-free preincubation, treatment groups (n=6) were incubated for a total of 56 hours
in 1.5 mL of proline-free, phosphate-free BGJb media containing 50pg/mL ascorbic acid,
50 pg/mL BAPN and one of seven doses of zinc: 0, 1.0, 1.5, 2.0, 5.0, 10.0, 20.0 umol/L.
3

[H]-proline (4 pCi/mL) was added for the final 32 hours of the incubation. Following

treatment incubations the conditioned media were collected into 12 x 75-mm
borosillicate glass test tubes. The cell layers were extracted with 0.75 mL of
0.2 mol/L NaOH by scraping with a disposable cell scraper. Each cell extract was then
pooled with the conditioned media that had been collected from that well. Bovine serum
albumin (1 mg/tube) was added to facilitate protein precipitation. Proteins were
precipitated by addition of 0.5 mL of ice-cold 50% TCA and 5% tannic acid. The pellets
were then washed by centrifugation and vortexed four times with 2 mL of
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ice-cold 10% TCA and 1% tannic acid, and once with 1 mL of ice-cold acetone. After air
drying for one hour, the pellets were resuspended in 0.4 mL of .05 N NaOH, vortexed and
stored overnight at 4° C. Duplicate 0.15 mL aliquots were removed from the
resuspensions and placed in fresh test tubes. The duplicate samples were neutralized by
the addition of 20 pi of 0.375 mol/L HC1. The distribution of collagenase-digestible
radioactivity ( [H]-proline) was determined by incubating one set of the duplicate
samples with 50 units of purified collagenase (Sigma type VII) in a reaction mixture
consisting of Tris buffer (0.1 mol/L, pH 7.4) and 0.2 mmol/L CaCl2. The second set of
duplicate samples were incubated in the same reaction mixture without added
collagenase. Following a three hour incubation at 37° C, the protein was precipitated
with 80 pi of ice cold 50% TCA and 5% tannic acid and centrifuged. Finally,
0.2 mL aliquots of the supernants were transferred to scintillation vials, and the
radioactivity of the samples was measured. Collagenase digestible protein was then
3

defined as the difference between the amounts of soluble [ H ]-proline in the tubes
containing collagenase and the minus-collagenase controls.

2. PREPARATION OF IGF II (Insulin-like Growth Factor II) POOLS
Cells were plated in replicate 100 mm culture dishes (n = 5) in
8 mL DMEM + 10% FCS at approximately 600,000 cells per dish and incubated
overnight. The following day the cells were rinsed once with 5 mL/dish of PBS then

29

incubated for 4 hours in serum-free DMEM. At the end of that preincubation, the media
were changed again to 5 mL/dish of effector medium (BGJb + 0.1% BSA +/- one of five
zinc doses ranging from 0 to 20 pmol/L). After 48 hours, 4 mL of the cell-conditioned
medium was collected from each sample and transferred to a 13 x 100-mm
polypropylene test tube, dried by Speed-Vac centrifugation, and stored at -20°C until the
time of IGF- assay. Prior to assay, the conditioned media samples were resuspended in
0.2 mL of 1 mol/L acetic acid, 50 pL of which was then applied to a IGF affinity gel
(Bio-Gel P-10) column. To prepare the columns, 10 g of Bio-Gel P-10 were hydrated
overnight at room temperature in 150 mL of 1 mol/L acetic acid + 0.1 mol/L NaCl. The
gel slurry was then degassed for 10 minutes with occasional swirling, and then allowed to
settle. Thirty milliliters of the supernant was transferred to a 50 mL tube. Circles of
0.6 cm diameter were cut from glass fiber filter paper (G6) using a standard three-hole
paper puncher and these circles were pre-soaked overnight in the 30 mL of supernant.
The soaked circles were inserted into Bio-Spin columns (a circle was laid flat on the
bottom of each column) and 3 mL of the gel slurry was then applied to each column
(applied in three 1 L aliquots with 5 minutes between aliquots to compact the gel). The
tops and bottoms of the columns were capped and stored at room temperature until use.
To remove excess buffer before use, each column was placed in a 12x 75-mm
polypropylene tube and centrifuged for 5 minutes in a swinging bucket at 3000 rpm
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(1250 x g) in a Beckman model T6J centrifuge (Beckman Instruments , Palo Alto, CA).
Fifty microliters of each acetic acid-resuspended sample was then applied to the center of
an individual Bio-Gel column and the columns were centrifuged again for 5 minutes to
collect the liquid. Fifty microliters of Bio-Spin elution buffer (1 mol/L acetic acid +
0.1 mol/L NaCl) was applied and the columns were centrifuged again. These volumes
contained the higher molecular weight fractions including the IGF-BPs. The columns
were then transferred to BSA-coated collection tubes. (These BSA-coated tubes were
prepared ahead of time by incubating 2 mL of DMEM media containing 4.6 mg/mL
Hepes and 1 mg/mL BSA for 3 hours at 37°C in 10 x 75-mm polypropylene tubes.)
Next, 1 mL of the elution buffer was added and incubated for 15 minutes at room
temperature, followed by another centrifugation for 7 minutes to elute the IGF pool
(IGF-I and IGF-II). An additional 0.5 mL of elution buffer was added and the 15 minute
incubation and 7 minute centrifugation procedures were repeated. The IGF pools were
combined and dried by Speed Vac centrifugation and stored at -20°C until use.

3. MEASUREMENT OF IGF-II CONTENT OF IGF POOLS
IGF-II in the cell conditioned media was measured by radioimmunoassay, using a
mouse monoclonal antibody to rat IGF-II. The IGF-containing samples from the Biospin
procedure were resuspended in 0.5 mL of 20 mmol/L acetic acid and duplicate aliquots
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(0.1 mL) of unknowns and standards (recombinant human IGF-II) were transferred to
polypropylene tubes containing 0.2 mL RIA buffer (40 mmol/L sodium phosphate,
pH 7.2, supplemented with 0.1% BSA and 0.02% sodium azide) and preincubated for
1 hour at room temperature on an automatic shaker with 0.1 mL primary antibody
(1:6000 dilution of 10 pg /mL). 125[ I ]IGF-tracer (0.1 mL recombinant human IGF-II)
was added and the tubes were incubated overnight at 4 °C. The IGF-tracer was
previously labeled with

125

[ I ] using chloramine T. The bound radioactive IGF-II was

separated from the free by adding 0.1 mL of a 1:30 dilution of non-immune mouse serum,
0.4 mL of 1:10 dilution of secondary antibody (a goat anti-mouse antibody) and
0.2 mL of 8% polyethylene glycol 8000. The samples were gently vortexed and
incubated for 2 hours at room temperature. The precipitates were pelleted by
centrifugation and the radioactivity of the pellets was determined. IGF-II concentration
was determined by comparison to the standards on a weight linear regression
displacement curve, plotting log [IGF-II] vs logit. The effective range of IGF-II was
0.025 to 6.25 ng/mL.

4. MEASUREMENT OF PTH-DEPENDENT cAMP
Replicate cultures of SaOS-2 cells (n = 6) were plated in 6-place multiwell plates at an
initial density of 500,000 - 750,000 cells per well in 2 mL of DMEM + 10% FCS and
incubated overnight. Following a PBS rinse and a two-hour incubation in serum-free
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DMEM media, the cells were exposed to phosphate-free media containing one of seven
doses of zinc (0, 1.0, 1.5, 2.0, 5.0, 10.0, 20.0) for 48-50 hours. The cells were then
-9

incubated for 20 minutes in serum-free DMEM containing 1x10' mol/L PTH and
1 mmol/L IBMX, a phosphodiester inhibitor. Parallel control plates were incubated in
serum-free DMEM containing 1 mmol/L IBMX alone (i.e. without the PTH). After the
20 minute exposure, the cell layers were extracted using 1.25 mL of an ice-cold
acid/ethanol solution (1 part 1 mol/L HC1: 99 parts 100% ethanol), then scraped and
transferred to 75 x 100 mm polypropylene test tubes. The acid-ethanol extracts were then
dried in a speed vacuum centrifuge and frozen at -20° C until they were analyzed for
cAMP levels.
The cAMP content of the cell extract pellets was quantitated with a commercially
available kit, the Biotrak cAMP enzymeimmunoassay system by Amersham. This kit
assesses the competition between unlabelled cAMP and a fixed level of enzyme-labeled
cAMP for a limited number of binding sites on an anti-cAMP antibody. cAMP levels
were determined by comparison to a standard curve of 0 to 3.2 fmol/well. Aliquots
(25 pL) of the extracts of cells exposed to PTH were diluted 1:1071 in the assay buffer
provided in the commercial kit. Aliquots (lOOpL) of the diluted samples and of the
undiluted extracts of cells which were not exposed to PTH were assayed for cAMP
levels. The amount of cAMP per culture well was calculated by multiplying the standard
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curve-derived value by the dilution factor (1071 for the PTH exposed extracts and 1 for
the non-PTH exposed extracts) and by the volume factor (50). The volume factor was
calculated by dividing the total volume of the extraction solution (1.25 mL) by the
volume of the aliquot (25 pL) assayed.

E. ALP mRNA MEASUREMENTS

1. RNA EXTRACTION
SaOS-2 cells were plated and incubated in forty-eight 100-mm dishes at a density of
500,000 to 750,000 cells per dish in 8 mL DMEM containing 10% PCS.
The following day, the media were replaced with serum-free DMEM for a 24 hour
preincubation. Following the preincubation, the cells were divided into 4 groups
(12 plates per group). Each group was incubated for 48 hours in BGJb medium
containing either 0 phosphate, 1.8 mmol/L phosphate, 10 pmol/L zinc, or the
combination of 1.8 pmol/L phosphate and 10 pmol/L zinc. At the end of the incubation,
three dishes from each group were rinsed once in approximately 2 mL of phosphate
buffer saline solution and stored for later measurement of ALP specific activity. The nine
remaining dishes in each treatment group were randomly divided into three subgroups
(three dishes per subgroup). The subgroups of dishes were then extracted in 2 mL/dish of
a solution containing 4 mol/L guanidium thiocynate, 0.025 mol/L citric acid
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(tri-sodium dihydrate), 0.5% N-lauroyl sarcosine and 0.7% 2-mercaptoethanol. The
extracts of each group of three dishes were pooled in a single 50-mL polypropylene test
tube, resulting in three RNA pools per treatment group (n = 3). The RNA pools were
then stored at -70°C until use. Before use, these extracts were thawed overnight at -20°C.
The pH of the extracts was adjusted to about pH 4 by the addition of 0.6 mL of
2 mol/L sodium acetate, pH 4, and the solutions were mixed for 30 seconds. Next, the
RNA was isolated from each extract by the addition of 6 mL of water-saturated phenol
and brief vortexing, followed by the addition of 1.2 mL of chloroform/isoamyl alcohol
(24:1) and mixing for 30 seconds. The RNA preparations were incubated on ice with
occasional mixing for 15 minutes, and the solution phases separated by centrifugation
(10,000 x g at 4°C) for 20 minutes. The RNA-containing aqueous phase of each solution
was transferred to a fresh 50-mL tube and the RNA was precipitated with an equal
volume of cold 2-propanol and incubated overnight at -20°C. The RNA was pelleted
(10,000 x g at 4°C) for 20 minutes. The pellets were resuspended in 0.5 mL of a solution
of 4 mol/L guanidium thiocynate, 0.025 mol/L sodium citrate and 0.7% of
2-mercaptoethanol and the resuspensions were transferred to 1.5-mL microfuge tubes.
An equal volume of 2°-propanol was added and the samples were incubated on dry ice
for 2 hours. Centrifugation under the conditions described earlier was performed. The
supernants were decanted, the RNA-containing pellets were rinsed two times with
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1 mL of 80% ethanol, and the samples were centrifuged again. The ethanol supemant
was discarded and the pellet was allowed to air dry for 5 minutes. The RNA pellets were
dissolved in 100 pmol/L DEPC water and stored at -70°C until use in the Northern blot
procedure.

2. NORTHERN GEL ELECTROPHORESIS AND BLOT ANALYSIS
Using an UV spectrophotometer, the optical density of each DEPC solution was
measured at 260 nm (OD26o) to determine the nucleic acid concentration of the RNA
preparations. Optical density readings of the same samples, using a 280 nm wavelength
(OD28o), were used to estimate the concentration of protein in each sample. The ratio of
OD260 : OD280 was calculated for each sample. All samples were found to be of sufficient
purity (approximately 1.8 : 1 for the OD260/OD280 ratio) for our Northern blot analyses.
The samples were aliquoted to fresh microfuge tubes in volumes calculated to yield
15 pg of RNA, based on the concentrations of RNA estimated from the UV absorption
measurements. Two and a half pL of loading dye (20 pmol/L EDTA pH 8.8,
0.25% Bromophenol Blue, 0.25% Xylene Cyanol and 50% glycerol) was added to each
sample aliquot, and then a volume of DEPC water was added to each tube to yield
25 pL total volume. To denature the RNA, the RNA-dye mixture was incubated at 65 °C
for 5 minutes and then loaded into a gel composed of 1% agarose dissolved in a MOPS
buffer solution (20 mmol/L MOPS, 5 mmol/L sodium acetate»3H20 and 0.5 mmol/L
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ethylene diaminetetraacetic acid (EDTA), pH 7.0), containing 6.6% formaldehyde. The
gels were then run for 5 hours on an OWL electrophoresis apparatus in the MOPS buffer
solution. The RNA was then transferred overnight to a Magnagraph (nylon transfer)
membrane by passive diffusion using 1.5 mol/L NaCl and 150 mmol/L citric acid, pH 7.
The RNA was crosslinked to the membrane by brief exposure to UV light. To identify
the 18S and 28S ribosomal RNA bands, the membranes were stained with a solution of
0.02% methylene blue dissolved in 500 mmol/L sodium acetate for 1 minute and rinsed
5 times in 500 mL of warm DEPC water. The locations of the 18S and 28S ribosomal
RNA bands were marked on the blots, and the density of the bands were measured with a
Zeineh Soft Laser Scanning Densitometer (Model SLR-2D/1D, Fullerton, CA). The blots
were probed for ALP mRNA and p-actin mRNA using 32P-labeled ALP(37) and p-actin(78)
cDNAs. The cDNA probes were labeled using a random primer by incubating 50 ng of
heat-denatured (5 minutes at 65°C and then quick cooled on ice for 30 seconds) cDNA
T9

with 50 pCi P-CTP, 20 pg of BSA, and 2 units of Klenow fragment enzyme in a
reaction buffer composed of 2 mol/L hepes, 250 mmol/L Tris-HCl, 25 mmol/L MgCl2,
0.3% 2-mercaptoethanol, 2 mmol/L dATP, 2 mmol/L dTTP, 2 mmol/L dGTP and
1 pg of commercially prepared hexamers. The reaction mix, which had a total volume of
50 pL was incubated at 37°C for 16 hours. Labeled probes were purified by using NAGS
Prepac cartridges. The final yield of labeled probes was 400 pL of ALP cDNA at
94,183 cpm/uL and 400 pL of the P-actin probe at 104,632 cpm/pL.
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Each blot was incubated in 4 mL of hybridization solution composed of
750 mmol/L sodium chloride, 50 mmol/L monobasic sodium phosphate,
5 mmol/L EDTA, 0.1% SDS, 1 g ficoll, 1 g polyvinylpyrrolidone, 1 g BSA(fraction V),
50% formamide and 200 pg/mL of boiled (5 minutes) herring sperm single-stranded
DNA, pH 7.4 for 2 hours at 42°C. Prior to hybridization, the aliquots of the cDNA
probes were mixed with 200 ug/mL of herring sperm single stranded DNA and the
mixtures were boiled for 5 minutes, cooled on ice and then added to the hybridization
solution. Hybridization of the ALP cDNA probe to the blots was done in 4 mL of
32

hybridization solution containing 2,000,000 cpm of the P-labeled ALP cDNA probe and
10% dextran sulphate. Hybridization of the p-actin cDNA probe was done in 4 mL of
hybridization solution containing 5,000,000 cpm of the actin probe. The blots were
incubated for 16 hours with the probes on an 42°C water bath with shaker. Following
hybridization, the blots were rinsed two times in a solution containing
900 mmol/L sodium chloride, 60 mmol/L monobasic sodium phosphate, 6 mmol/L
EDTA and 0.1% SDS (pH 7.4) for 15 minutes at 42°C, then two times in a solution of
150 mmol/L sodium chloride, 10 mmol/L monobasic sodium phosphate,
1 mmol/L EDTA and 0.1% SDS, pH 7.4 at 42°C for 15 minutes and once more in the
most dilute rinse solution at 55°C for 15 minutes. ALP mRNA and P-actin mRNA levels
were determined by exposing the hybridized blots to Kodak MS and Fuji RX medical
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x-ray film, respectively. The autoradiographs were scanned by densitometery to obtain
area under the curve measurements. The peak area of each band was normalized to the
p-actin measurement to correct for uneven loading. Normalization of the peak area of
each band to the 18S and 28S band densitometry measurements was also performed.

F. PARTIAL PURIFICATION OF ALP
SaOS-2 cells were plated in sixty-seven 100-mm dishes, rinsed in preincubated in
serum-free DMEM to remove residual FCS and then incubated for 48 hours in 8 mL of
calcium-free BGJb media. Calcium has been shown to decrease membrane vesicle ALP
stability (unpublished), so calcium was excluded from the incubation medium. The
cell-conditioned medium from multiple dishes was pooled to yield a total volume of 500
mL. To this crude preparation of extracellular ALP activity, 1000 units of
commercially-prepared phospholipase C (from B. cereus) was added and the mixture was
incubated, with constant stirring, for 48 hours at 4 °C. This incubation was intended to
cleave the glycan phosphatidylinositol (GPI) anchor which attaches skeletal ALP to the
outer plasma membrane (and the outer surface of membrane vesicles). Phospholipase C
incubation effectively converts sALP from an insoluble (hydrophobic) form to a soluble
(hydrophillic) form. At the end of the incubation, the enzyme preparation was filtered
with a 0.22 micron filter to remove insoluble material. The preparation was then
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concentrated with Aquacide and dialyzed (using a 12,000 molecular weight cutoff
dialysis membrane) against a tris-bicarbonate buffer solution (12.5 mmol/L tris,
12.5 mmol/L sodium bicarbonate, containing 10 fimol/L zinc dichloride, pH 7.5). The
zinc was included to ensure that activity was not lost because of zinc dissociation. A
polysaccharide affinity column (concanavalin A agarose) was poured and washed with
the tris-bicarbonate buffer prior to sample loading. The phospholipase C-treated
cell-conditioned medium dialysate was applied to the column and another wash with
buffer was performed. The column was then eluted with 30 mL volumes of column
buffer containing 1, 100, 300, and 500 mmol/L a-methyl mannoside. Fractions were
collected by volume with an automated fraction collector according to volume (110 drops
per fraction tube). Each fraction was assayed for ALP activity and total protein.
Fractions # 10 through #13, which corresponded to the ALP activity peak in 100 mmol/L
of a-methyl mannoside, were pooled, concentrated with Aquacide, and dialyzed against
the buffer solution. The concentrated dialysate of the concanavalin A column was
applied to a Sepharose CL - 6B200 molecular sieve column and eluted with the dialysis
buffer. As before, fractions were collected, the ALP activities and total protein
concentrations of the fractions were determined, and the fractions corresponding to the
ALP activity peak (#11 - 14) were pooled yielding a total volume of 16.2 mL.
In order to monitor the enzyme yield throughout the purification process, aliquots of
the crude extract, the concentrate following phospholipase C treatment, the
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concanavalin A pooled fractions (#10-13) and the sepharose pooled fractions (#11 - 14)
were assayed for ALP activity and total protein, and ALP specific activities were
calculated. The relative purification at each step was calculated as the ALP specific
activity of each preparation divided by the ALP specific activity of the original crude
extract. Percent recovery was determined as the total ALP activity recovered at each
step, divided by the total ALP activity in the pooled cell-conditioned times 100.

G. MEASUREMENT OF RADIOACTIVELY-LABELED SAMPLES
3

•

The radioactivity of samples containing [ H ]-proline, or

32

[ P ] were measured using

a Beckman LS 5800 series Liquid Scintillation System. Samples containing

125

[ I ] were

assessed using a Micromedic Mode 4/600 Plus Automatic Gamma Counter.

H. MOUSE STUDY
Forty Swiss-Webster female adult mice were randomly assigned to one of five
treatment groups (n=8/group). Initial total body weights for each mouse were determined
and each mouse was tagged (ear-punch hole) for future identification. The following
dietary treatments were applied for four weeks or six weeks: (a) a Zn-deficient diet
(Harlan Teklad diet TD 85419); (b) a normal diet (TD 85420 - yielding

41

0.45 mg ZnC03/mouse/day); (c) a normal diet supplemented with 116 mg/L ZnAc in the
drinking water (to yield a total zinc intake of approximately 2x that provided by the
normal diet); (d) a normal diet supplemented with 232 mg/L ZnAc in the drinking water
(to yield a total intake of approximately 3x the normal diet); and (e) a normal diet
supplemented with 348 mg/L ZnAc (to yield a total intake of approximately 4x the
normal diet). After the treatment period, final body weights were measured and the mice
were euthanized (under ethrane anesthesia). Blood samples were collected and
centrifuged for ten minutes at 1600 rpm for serum isolation. Twenty-five pi of serum
was diluted (1:10) for measurement of ALP activity. Calvaria and tibia were dissected
using anatomical landmarks to minimize variation in dissection, and incubated overnight
at 4 °C in phosphate buffer saline (PBS) to remove marrow cavity cells and serum.
(Note: tibia were cut in half prior to PBS incubation to facilitate this rinsing process.)
Following the PBS rinse, the bones were extracted in 1.5 mL of 0.01% triton X-100 with
0.01% sodium azide for 72 hours. These extracts were used to measure the skeletal
contents of protein and ALP activity. Following the triton extraction process, the bones
were transferred to 1.5 mL of ethanol for 4 hours and then dried at 37°C overnight for
determination of dry weights.
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I. STATISTICAL ANALYSIS
Data shown are averages of replicates (usually, mean ± SEM). Analysis of variance,
linear regression and Pearson correlation analysis were performed using Systat statistical
software (Systat, Inc., Evanston, IL). To minimize the potential effects of interassay
variation, statistical methods were only applied to intrassay group comparisons.

RESULTS

A. Specific Aim I: To characterize the effect of zinc on alkaline phosphatase
activity and on hone cell metabolic processes in the human osteoblast-like
osteosarcoma cell line. SaOS-2 and in normal human bone cells.

1. DESCRIPTION OF THE PHOSPHATE AND ZINC EFFECTS
Data from previous studies (57,58) indicated that phosphate levels positively regulate
the level of ALP specific activity in SaOS-2 cells. It was also determined (unpublished)
that incubation with low levels of zinc increased ALP specific activity in these cells.
Figure 3 illustrates these associations and the observed ability of zinc (Zn) to maintain
ALP activity in the absence of phosphate (Pi). After plating and serum-free
preincubation, replicate cultures of SaOS-2 cells (n=6) were incubated for 24 hours in one
of the following four different BGJb media solutions: 1.8 mmol/L Pi, 0 Pi,
0 Pi + 10 pmol/L Zn, and 1.8 mmol/L Pi + 10 pmol/L Zn. ALP activity (U/mL) and
total protein concentrations (mg/mL) were measured in cell layer extracts and specific
activities (U/mg protein) were calculated. Reported p-values represent comparisons to
the 1.8 mmol/L Pi control cells. As observed in other studies, the level of phosphate in
the media affected the level of ALP. In the absence of phosphate, ALP specific activity
was significantly decreased. This effect of phosphate level on ALP activity is surprising

43

Figure 3. Effects of Zinc and Phosphate on ALP Specific Activity. AI.P activity in SaOS-2 cells was decreased in the
absence of phosphate (Pi) and increased in the presence of zinc (Zn). Replicate cultures (n=6) were incubated 24 hours in
serum-free BGJb medium containing 1.8 mmol/L Pi, 0 Pi, 0 Pi + 10 pmol/L Zn, or 1.8 mmol/L Pi + 10 pmol/L Zn. ALP
specific activity was measured as U/mg protein and is expressed as mean ± SEM. * Difference from 1.8 mmol/L Pi controls,
p< 0.001.
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since phosphate is a product inhibitor of the ALP reaction and competes with the
phosphoryl substrate. In the presence of zinc, this effect of phosphate withdrawal on
ALP specific activity did not occur. Furthermore, in the zinc-treated cells, ALP specific
activity was significantly increased over control values. No additive nor synergistic
effect of the combination of zinc and phosphate was observed in the 1.8 mmol/L Pi +
10 pmol/L Zn treatment groups when compared to the zinc alone treatment group.

2. DOSE-DEPENDENT EFFECTS OF ZINC +/- PHOSPHATE ON PROTEIN
AND ALP SPECIFIC ACTIVITY
To investigate the effect of zinc at high and low phosphate concentrations, replicate
cultures of SaOS-2 cells (n=6) were incubated in media containing one of eleven different
concentrations of zinc: 0, 0.1, 0.2, 0.5, 1.0, 2.0, 5.0, 10.0, 20.0, 50.0, 100.0 and
200.0 pmol/L Zn in the presence (1.8 mmol/L) or absence of phosphate for a total of
48 hours. As seen in Figure 4, the amount of cell layer protein was not significantly
affected by zinc at either phosphate concentration, except for a decrease at extremely high
doses of zinc (100 and 200 pmol/L). We attribute the observed decrease in total protein
at these doses to zinc toxicity. Because of this adverse effect on cell layer protein, values
for these high doses of zinc were omitted from our calculations of ALP specific activity.
Figure 5 is a plot of calculated ALP specific activity vs log zinc concentration (pmol/L).
In the absence of phosphate, a hyperbolic relationship between ALP specific activity and

Figure 4. Dose-Dependent Effects of Zinc on Total Protein. Amount of total cell layer protein of SaOS-2 cells was not
effected by zinc (Zn), with or without 1.8 mmol/L phosphate (Pi), at doses below 50 pmol/L Zn. Replicate cultures (n=6) were
incubated 48 hours in serum-free BGJb medium containing 0 - 200 pmol/L Zn. At 100 and 200 pmol/L Zn total cell layer
protein was decreased due to zinc toxicity. Total cell layer protein was measured as pg/mL protein and is expressed as mean ±
SEM. * Difference from 0 zinc controls, p < 0.005.
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Figure 5. Dose-Dependent Effects of Zinc on ALP Specific Activity. The effect of zinc (Zn) on ALP specific activity in
SaOS-2 cells was dependent on the phosphate (Pi) concentration. In the absence of Pi, significant increases in ALP specific
activity were observed at doses above 2 pmol/L Zn. In the presence of 1.8 mmol/L Pi, ALP specific activity was significantly
increased by doses of 2 and 5 pmol/L Zn. Replicate cultures (n=6) were incubated 48 hours in serum-free BGJb medium
containing 0-50 pmol/L Zn. Note the logarithmic scale on the horizontal axis. ALP specific activity was measured as
U/mg protein and expressed as mean ± SEM. * Difference from 0 Zn controls, p < 0.005.
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log [Zn] was observed. The estimated Km (i.e. the dose of zinc required to elicit half the
maximal effect on ALP activity) for zinc in the absence of phosphate was about Ipmol/L.
Zinc doses above 2 pmol/L significantly increased ALP specific activity. This
hyperbolic relationship was not observed when 1.8 mmol/L phosphate was present in the
medium. Even in the presence of 1.8 mmol/L phosphate, ALP specific activity was
significantly increased at 2 and 5 pmol/L zinc.

3. TIME-DEPENDENT EFFECTS OF ZINC AND PHOSPHATE ON ALP
SPECIFIC ACTIVITY
To further characterize the zinc effect, ALP specific activity levels were measured as a
function of time with and without zinc. SaOS-2 cells were plated and preincubated in
serum-free DMEM and then incubated in one of four effector media (1.8 mmol/L Pi, 0 Pi,
0 Pi + lOpmol/L Zn, or 1.8 mmol/L Pi + 10 pmol/L Zn) for 0, 6, 12, 24, 48, 72, or
96 hours. Significant cell death was observed in the cells incubated for 96 hours,
therefore, those results were omitted from this analysis. At each time point, the
cell-conditioned media were removed, and the cell layers were rinsed with PBS and
immediately frozen at -20°C. Cell layers from all time points were extracted and ALP
activity and protein concentrations were measured simultaneously to eliminate interassay
variation. Figure 6 shows the ALP specific activity of the cell layers at each time point.
The p-values indicated reflect significant changes compared to control cells at

Ln

Figure 6. Zinc/Phosphate Effects Over Time. Time dependent increases in ALP specific activity in SaOS-2 cells occurred
over 72 hours in the presence of phosphate (Pi) and zinc (Zn), alone or in combination. Replicate cultures (n=6) were incubated
in serum-free BGJb medium containing 1.8 mmol/L Pi, 0 Pi, 0 Pi + 10 pmol/L zinc, or 1.8 mmol/L Pi + 10 pmol/L zinc. ALP
specific activity was measured as U/mg protein and is expressed as mean ± SEM. * Difference from 0 hour controls,
p< 0.001.
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1.8 mmol/L Pi and 0 Pi + 10 jamol/L Zn treatment groups. Results of the Pi/Zn
combination (treatment #4) are omitted from Figure 4, however, the values observed for
this group were nearly identical to those observed in the 0 Pi + 10 pmol/L Zn group).
Furthermore, at time points longer than 24 hours, zinc treatment significantly raised ALP
specific activity levels when compared to the 1.8 mmol/L Pi-treated cells. No additive
effect was observed in the Pi/Zn combination treated cells.

4. EFFECT OF CELL DENSITY ON THE EFFECTS OF ZINC AND PHOSPHATE
TO INCREASE ALP SPECIFIC ACTIVITY
An additional characterization experiment was performed to assess the influence of
cell density on the observed effect of zinc to increase ALP activity (data not shown).
SaOS-2 cells were plated at 25,000, 50,000, 100,000, 200,000 and 250,000 cells/well in
24-place multiwell dishes (n=6). After serum-free preincubation, groups of cells were
incubated in each of four treatment media (1.8 mmol/L Pi, 0 Pi, 0 Pi + lOpmol/L Zn, or
1.8 mmol/L Pi + 10 pmol/L Zn) for 24 hours. The results of these studies showed that
cell density slightly affected ALP specific activity values (i.e. the specific activity of cells
plated at 50,000 cells/well was 6.67 U/mg protein, whereas, those plated at
250,000 cells/well had a specific activity of 4.39 U/mg protein, p < .001). The previously
characterized effects of zinc on ALP specific activity, however, were observed at all cell
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densities. In other words, phosphate withdrawal resulted in a 59-68% reduction in ALP
specific activity compared to control (1.8 mmol/L Pi) extracts, whereas, treatment with
zinc alone or in combination with phosphate showed specific activity levels which were
125 - 147% and 122 - 156% of control values, respectively. These data suggest that cell
density does not influence the effect of zinc to increase ALP specific activity.

5. CAN THE EFFECT OF ZINC TO INCREASE ALP SPECIFIC ACTIVITY ALSO
BE OBSERVED WITH OTHER DIVALENT CATIONS?
To determine whether the effects of zinc to maintain and increase ALP activity in the
absence of phosphate are unique to that metal atom, replicate cultures of SaOS-2 cells
(n=6) were incubated for 48 hours in 0 Pi media with and without three doses (2, 10, and
20 pmol/L) of each of the following divalent metal ions: zinc, calcium, cobalt, copper,
iron, magnesium and manganese. Figure 7 shows the ALP specific activity measured in
the 0 and 1.8 mmol/L Pi controls and in the cultures that were incubated with the
20 pmol/L dose of each tested metal. As expected, ALP specific activity in cells
incubated without phosphate was significantly decreased compared to the 1.8 mmol/L Pi
controls. Application of all metals except zinc also resulted in a significant decreases in
ALP specific activity. In contrast, the zinc-treated cells showed nearly a two-fold
increase in ALP specific activity.

oi

Figure 7. Divalent Cation Specificity. ALP specific activity in SaOS-2 cells was increased in the presence of zinc and
decreased in the presence of other divalent metal ions. Replicate cultures (n=6) were incubated 24 hours in serum-free BGJb
medium containing 20 pmol/L doses of zinc (Zn), calcium (Ca), cobalt (Co), copper (Cu), iron (Fe), magnesium (Mg), and
manganese (Mn). ALP specific activity was measured as U/mg protein and is expressed as mean ± SEM. * Difference from
1.8 mmol/L Pi controls, p < 0.001.
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6. IS THE EFFECT OF ZINC TO INCREASE ALP SPECIFIC ACTIVITY UNIQUE
TO SaOS-2 CELLS?
To determine if the observed effect of zinc to increase ALP specific activity was
unique to the SaOS-2 cell line, the four standard treatments (0 Pi, 1.8 mmol/L Pi,
10 pmol/L Zn, and 1.8 mmol/L Pi + 10 pmol/L Zn) were applied for 48 hours to
MG-63 cells (an osteosarcoma-derived cell line) and to two normal human bone cell
lines (HBV-146 and HBV-155), and the specific activities of ALP in the cell extracts
were determined. The normal human bone cell lines were obtained from the
Cooperative Human Tissue Network, which is supported by the National Cancer
Institute. The cells were cultured from the discarded vertebral tissue from neurosurgical
procedures. The skeletons of the patients donating the tissue were considered to be free
of bone disease. Comparison of the results from the different cell lines showed a wide
range in the absolute level of ALP activity. For example, in control wells incubated with
BGJb media (containing 1.8 mmol/L phosphate), we had previously found that
SaOS cells have a basal ALP specific activity of about 10 U/mg or 10,000 mU/mg. In
contrast, the specific activities of control wells in the MG-63, HBV-146 and HBV-155
cells were 3.9, 59.0, and 9.6 mU/mg, respectively. ALP specific activities in each of the
four cell lines (including SaOS-2) are expressed as percent of control (1.8 mmol/L Pi) in
Figure 8. Treatment with phosphate-free media produced relative decreases in the
MG-63 and HBV-146 cells similar to the decreases previously observed in the

U1

Figure 8. Effects of Zinc and Phosphate on ALP: Bone Cell Specificity. The effects of zinc (Zn) and phosphate (Pi) on
ALP specific activity were observed in a variety of human osteoblast-line cells. Replicate cultures (n=6) of SaOS-2, MG-63,
HBV-146 and HBV-155 cells were incubated 24 hours in serum-free BGJb medium containing 1.8 mmol/L Pi, 0 Pi,
0 Pi + 10 pmol/L Zn, or 1.8 mmol/L Pi + 10 pmol/L Zn. ALP specific activity was measured as U/mg protein and is expressed
as mean ± SEM. * Difference from 1.8 mmol/L Pi controls, p < 0.001.
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SaOS cells. For SaOS-2 cells, withdrawal of phosphate produced a 59-68% decrease in
ALP specific activity. Phosphate withdrawal caused a 66% decrease and a 70%
decrease in ALP specific activity in MG-63 and HBV-146 cells, respectively.
Surprisingly, the absence of phosphate had no effect on the cell layer ALP specific
activity in the HBV-155 cells (99.6% of control). In SaOS-2 cells with 1.8 mmol/L Pi,
zinc increased ALP specific activity 125 - 147% (p < 0.001). Zinc caused similar
increases in all three of the other cell lines: 141% of control for MG-63 cells, 116% of
control for HBV-146 cells and 139% of control for HBV-155 cells (p < .001 in all
cases). Analysis of the groups treated with the combination of 1.8 mmol/L Pi and
10 pmol/L Zn showed values very similar to the zinc alone treatment group data.

7. DOSE-DEPENDENT EFFECTS OF ZINC ON COLLAGEN SYNTHESIS
In subpopulations of SaOS-2 cells which differ in ALP specific activity, the amount
of collagen synthesis is proportional to the ALP specific activity,(55) suggesting that
subpopulations with high levels of ALP may be more osteoblastic than those with low
levels of ALP. Cells treated with bone formation stimulating agents such as fluoride and
calcitonin(59) also demonstrate increased collagen production. The potential effect of zinc
on collagen production was assessed by determining the amount of radioactively labeled
proline released during collagenase digestion of cell-conditioned medium preparations
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derived from SaOS-2 cells that had been incubated with one of the following seven doses
of zinc: 0, 1.0, 1.5, 2.0, 5.0, 10.0, or 20.0 |amol/L. Parallel cell cultures which were not
radioactively labeled were prepared for the measurement of ALP specific activity over
the same range of zinc doses. Figure 9 summarizes the results of this experiment. As
before, increasing doses of zinc were associated with increased ALP specific activity with
a maximal effect observed at the doses above 5 pmol/L. In contrast, zinc had no apparent
effect on the amount of collagenase digestible protein, suggesting that zinc does not affect
collagen production in these cells.

8. DOSE-DEPENDENT EFFECTS OF ZINC ON PTH-LINKED SYNTHESIS OF
cAMP
Previous studies (55) have shown that in subpopulations of SaOS-2 cells which differ
in ALP specific activity, the amount of PTH-dependent cAMP production is proportional
to the ALP specific activity. The effect of zinc on PTH-dependent cAMP production
was assessed by determining the amount of cAMP produced in the presence and absence
of parathyroid hormone (PTH) in the extracts of SaOS-2 cells that had been incubated
for 48-50 hours with one of the following seven doses of zinc: 0, 1.0, 1.5, 2.0, 5.0, 10.0,
or 20.0 pmol/L. At the end of these incubations, half of the cell cultures received a
20 minute exposure to media containing 1 x 10’9 mol/L PTH and 1 mmol/L IBMX. The
other half of the cells cultures were exposed to media containing only IBMX. The cells

cn
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Figure 9. Effects of Zinc on Collagenase Digestible Protein and on ALP Specific Activity. Zinc caused dose-dependent
increases in ALP specific activity (circles) in SaOS-2 cells, but had no effect on collagen digestible protein (CDF) synthesis
(triangles). Replicate cultures (n=6) were incubated 40 + 16 hours in serum-free, phosphate-free BGJb medium containing
0-20 pmol/L zinc. CDP synthesis was measured by incorporation of [3Hj-proline into CDP during the final 16-hours of
incubation in serum-free, low proline BGJb (1% of normal proline) with 50 ug/mL BAPN and 50 ug/mL ascorbate and is
expressed as cpm/well. ALP specific activity was measured as U/mg protein and is expressed as mean ± SEM. * Difference
from 0 zinc controls, p < 0.001.
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were then extracted and cAMP in the cell extracts was determined using an
enzymeimmunoassay kit. Parallel plates were subjected to the same treatments and
extracted for measurement of ALP specific activity.
Analysis of the ALP level in the cell extracts of the parallel plates showed the
characteristic increases in ALP specific activity with increasing zinc doses, as observed in
previous studies, but no effect on cell layer protein. Exposure to PTH resulted in marked
increases in cAMP, in that, over 300-times more cAMP was measured in the extracts of
cells which received pulse treatment with PTH than was measured in the extracts of cells
pulsed with medium only. In the extracts of cells which received a pulse incubation with
medium which did not contain PTH, no significant effect of zinc on the level of cAMP
was observed. In the extracts of cells which received a pulse incubation with medium
containing PTH, however, a biphasic dose-dependent relationship between zinc dose and
cAMP levels was seen. Figure 10 shows the plot of concentration of PTH-dependent
cAMP (left vertical axis) vs zinc dose and the plot of ALP specific activity (right vertical
axis) vs zinc dose. Compared to zinc-free controls, significant increases in
PTH-dependent cAMP levels were observed in the extracts of cells incubated in media
containing 1.5 and 2 pmol/L zinc, but not in the extracts of cells incubated in media
containing higher zinc doses. In contrast, extracts of cells incubated with increasing zinc
doses had significantly increased ALP specific activity at all doses of zinc compared to
the zinc-free control group. A maximal effect of zinc on PTH-dependent cAMP was

O'*
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Figure 10. Effects of Zinc on PTH-Dependent cAMP and on ALP Specific Activity. Dose dependent changes are
observed in the plots of concentration of PTH-dependent cAMP (left vertical axis) vs zinc dose and of ALP specific activity
(right vertical axis) vs zinc dose. Compared to controls, significant increases in PTH-dependent cAMP levels (triangles) were
observed in the extracts of replicate SaOS-2 cell cultures incubated in media containing 1.5 and 2 pmol/L zinc and pulsed for
20 minutes with 1 x 10’9 mol/L PTH, but not in the extracts of cells incubated in media which contained higher zinc doses and
also received the PTH treatment. Extracts of cells were incubated with increasing zinc doses had significantly increased ALP
specific activity (circles) at all doses of zinc compared to the zinc-free control group. PTH-dependent cAMP production was
measured by an enzymeimmunoassay system as pmol/well and is expressed as mean ± SEM. Specific activity was measured
as U/mg protein and is expressed as mean ± SEM. * Difference from 0 zinc controls, p < 0.025.
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observed at 1.5 ]j,mol/L zinc with cAMP levels increasing 167% above the zinc-free PTH
treated controls, whereas the maximal effect of zinc on ALP specific activity at this same
dose was 346% of the controls.

9. DOSE-DEPENDENT EFFECTS OF ZINC ON IGF-II SYNTHESIS
To determine if zinc has an effect on the net synthesis of IGF-II by SaOS-2 cells,
replicate cell cultures were incubated for 48 hours in effector media containing BSA and
one of five zinc doses (0, 2, 5, 10, or 20 pmol/L). Eighty percent (4 of 5 mL) of the
cell-conditioned media was used to assay for IGF-II content. The cell layers were
extracted and assayed for ALP activity and total protein. IGF (IGF-I and II) was
separated from IGF-binding proteins in the conditioned media by means of IGF affinity
Biospin gel columns. The IGF-II content of the samples was determined by
radioimmunoassay, using a mouse monoclonal antibody to rat IGF-II. As before, we
found that the ALP specific activity of the cell extract was significantly increased with
increasing zinc doses, with a maximal effect observed at doses above 5 pmol/L. The
ALP activity measured in the cell-conditioned media was also positively associated with
the zinc concentration. In contrast, as seen in Figure 11, measurement of the IGF-II
content of the cell-conditioned media by RIA and calculation of Pearson correlations
showed a statistically significant negative association between zinc dose and the level of
IGF-II (r = -.451, p < 0.024). Further analysis showed that IGF-II content of the
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Figure 11. Effects of Zinc on IGF-II and on ALP Specific Activity. Net production of Insulin-like Growth Factor II
(IGF-II) (triangles) by SaOS-2 cells was inversely proportional to the dose of zinc (r = -0.51, p < 0.005) whereas ALP specific
activity (circles) was proportional to the zinc dose. Replicate cultures (n=6) were incubated 48 hours in serum-free BGJb
medium containing 0.1 % BSA and 0-20 pmol/L zinc. IGF-II was measured in the cell-conditioned medium, assayed as
described in the text and is expressed as ng/mL. ALP specific activity was measured as U/mg protein and is expressed as mean
± SEM. * Difference from 0 zinc controls, p < 0.001.
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cell-conditioned media was also negatively correlated to the ALP specific activity of the
cell extract (r = -.384, p < 0.04) and to the ALP specific activity of the cell-conditioned
media (r = -0.481, p < .008).

10. DOSE-DEPENDENT EFFECTS OF ZINC ON ACID PHOSPHATASE
ACTIVITIES
To determine whether zinc could also affect the activity of another bone cell
phosphatase, we measured the dose-dependent effects of zinc on acid phosphatase (AcP)
activities. SaOS-2 cells were plated in 6-place multiwell plates. Following preincubation
for 2 hours in serum-free media and incubation for 48 hours in phosphate-free BGJb
media with one of seven doses of zinc (0, 1.0, 1.5, 2.0, 5.0, 10.0, or 20.0 pmol/L).
Triton X-100 extracts of the cell layers were assayed for ALP specific activity, total AcP
specific activity, tartrate-resistant AcP (TRAP) specific activity and fluoride-sensitive
AcP specific activity. Table 1 summarizes the results of a Pearson correlation analysis of
the data. Zinc dose was positively correlated with ALP specific activity and total AcP
specific activity. ALP specific activity was positively correlated with both total AcP
activity and TRAP activity but not with fluoride-sensitive AcP activity.

ro

Table 1. Effects of Zinc on AcP Activities. Pearson correlation analysis of the effects of zinc on ALP and acid phosphatase
(AcP) specific activities in SaOS-2 cells. Replicate cultures (n=6) were incubated 48 hours in serum-free, phosphate-free BGJb
medium containing 0-20 pmol/L zinc. ALP specific activity (ALP SA), total acid phosphatase specific activity
(Total AcP SA), tartrate-resistant acid phosphatase specific activity (TRAP SA), and fluoride-sensitive acid phosphatase
specific activity (F-sensitive SA) were measured as U/mg protein and are expressed as mean ± SEM. R-values represent all
individual data points (n = 42), not group mean values.

Index

Co variate

r-value

p-value

Zinc dose (pmol/L)

ALP SA

0.80

<0.001

Zinc dose (pmol/L)

Total AcP SA

0.32

<0.05

Zinc dose (pmol/L)

TRAP SA

0.25

NS

Zinc dose (pmol/L)

F-sensitive AcP SA

0.15

NS

ALP SA(U/mg)

Total AcP SA

0.43

< 0.004

ALP SA (U/mg)

TRAP SA

0.44

< 0.004

ALP SA (U/mg)

F-sensitive AcP SA

0.08

NS
-j

LJ
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11. DOSE DEPENDENT EFFECTS OF ZINC ON PROTEIN SYNTHESIS
In previous studies zinc increased protein synthesis in rat osteoblast cultures. (29,30,43)
To determine if zinc has a similar effect in human osteosarcoma cells, we incubated
replicate cultures of SaOS-2 cells in low proline, phosphate-free media with one of 7
doses of zinc (0, 1.0, 1.5, 2.0, 5.0, 10.0, or 20 pmol/L) for a total of 48 hours. After the
first 32 hours of the incubation, radioactively-labeled proline was added to the media and
the amount of radioactive proline incorporated into the cell layer was determined as a
measure of new protein synthesis during the final 16 hours. Parallel 24-place multiwell
plates which did not receive radioactive proline were also prepared, and the cell extracts
of these cells were used to measure ALP specific activity. As seen in Figure 12,
incubation with increasing zinc doses resulted in the expected increase in ALP specific
activity with a maximal effect observed at doses above 5 pmol/L. In contrast, the amount
of incorporated radioactive protein was not changed with increasing doses of zinc
suggesting that zinc has no effect on protein synthesis in SaOS-2 cells.
Table 2 shows a comparison of the effect of zinc on ALP specific activity and on other
bone cell metabolic processes. Total acid phosphatase, collagenase digestible protein,
tritiated proline incorporation, IGF-2 synthesis and PTH-dependent cAMP production
measurements of cells incubated in media containing 5 and 10 umol/L zinc from several
different experiments are listed, along with the ALP specific activity of cells incubated

-J
Ln

Figure 12. Effects of Zinc on Protein Synthesis and on ALP Specific Activity. Zinc caused dose-dependent increases in
ALP specific activity (circles) in SaOS-2 cells but had no effect on protein synthesis (triangles). Replicate cultures (n=6) were
incubated 32+16 hours in serum-free, phosphate-free BGJb medium containing 0-20 pmol/L zinc. Protein synthesis was
measured by incorporation of [3H]-proline into newly synthesized protein during the final 16-hours of incubation in serum-free,
low proline BGJb (1% of normal proline) with 50 ug/mL BAPN and 50 ug/mL ascorbate and is expressed as cpm/well. ALP
specific activity was measured as U/mg protein. All values are expressed as mean ± SEM. * Difference from 1.8 mmol/L Pi
controls, p < 0.001.

v£)

t"-

l/iouiil [oujz]
O)

£

03

SI-

(H

s

0

CO

0

I

z>

-U

s

o

II MM*

■MM ■

>

O

01^

O
“U

<

o

SI

O
0)
CL

oz

■ mmm

0)
CL
<

S3

<D
3

3 o
o

'l
$

I

TJ

O
0)

o

3

-J

Table 2. Summary of the Effects of Zinc on ALP Specific Activity and on Other Bone Cell Parameters. The results of
five experiments in SaOS-2 cell cultures. Total acid phosphatase, collagenase digestible protein, [H]-proline incorporation,
IGF-2 synthesis and PTH-dependent cAMP production in cells were incubated in media containing zinc from several different
experiments were measured in the cell extract or in the cell-conditioned medium and the results are listed along with the ALP
specific activity of the extracts of cells incubated under the same zinc doses and experimental conditions. ALP specific
activity was significantly increased by 5 and 10 pmol/L doses of zinc with increases ranging from 180% of control to 591% of
control. No other measured metabolic function showed comparable magnitude of change. Values are reported as percent of
control.

5 fimol/L zinc (% of control)
Parameter

Parameter

ALP SA

10 (imol/L zinc (% of control)
Parameter

ALP SA

Total Acid Phosphatase

108

550

96

591

Collagenase Digestible Protein

96

306

112

333

3[H]-Proline Incorporation

108

299

87

326

IGF-II Synthesis

91

188

91

180

PTH-Dependent cAMP

118

550

129

591

CO
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under the same zinc doses and experimental conditions. To facilitate comparison, the
values are reported as percent of control. In each experiment, ALP specific activity was
significantly increased by these doses of zinc with increases ranging from 180% of
control to 591% of control. In contrast, no other measured metabolic function showed
comparable magnitude of change.

B. SPECIFIC AIM II - To determine the mechanism bv which zinc affects the level
of ALP activity in human osteoblast-like cells.

1. CAN ZINC AND/OR PHOSPHATE REVERSE THE LOSS OF ALP ACTIVITY
THAT RESULTS FROM PHOSPHATE WITHDRAWAL?
As a means of exploring the mechanism by which zinc maintains and increases ALP
specific activity, we tested the hypothesis that treatment with 1.8 mmol/L Pi and/or
10 pmol/L zinc could reverse the reduction in ALP specific activity that was caused by
phosphate withdrawal. After plating and serum-free preincubation, replicate cultures of
SaOS-2 were incubated in 0.5 mL of 0 Pi media for 24 hours. Four treatment media
(1.8 mmol/L Pi, 0 Pi, 0 Pi + lOpmol/L Zn, or 1.8 mmol/L Pi + 10 pmol/L Zn) were then
applied and the cells were incubated for an additional 24 hours or 48 hours. As shown in
Figure 13, at both time points, treatment with both phosphate and zinc, alone or in
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Figure 13. Zinc Reverses the Effect of Phosphate Withdrawal. ALP specific activity loss due to phosphate withdrawal is
reversed by zinc (Zn) and phosphate (Pi) in SaOS-2 cells. Replicate cultures (n=6) were preincubated 24 hours in serum-free,
phosphate-free BGJb medium, then incubated an additional 48 hours in serum-free BGJb medium containing 1.8 mmol/L Pi,
0 Pi, 0 Pi + 10 pmol/L Zn, or 1.8 mmol/L Pi + 10 pmol/L Zn. ALP specific activity was measured as U/mg protein and
expressed as mean ± SEM. *Difference from 0 mmol/L Pi, 0 hour controls, p < 0.001.
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combination, resulted in significantly higher ALP specific activities when compared to
the 0 Pi controls. In addition, when compared to the 1.8 mmol/L Pi-treated groups within
each time point, all treatments containing zinc (0 Pi + 1 Opmol/L Zn and
1.8 mmol/L Pi + 10 pmol/L Zn) had significantly increased ALP specific activity
(p<.001). These data suggest that the addition of Pi and/or zinc can inhibit or reverse the
effect of phosphate withdrawal on cell layer ALP specific activity. This experiment,
however, does not indicate the means by which this reversal occurs. Further studies are
required to determine the mechanism of this zinc-dependent recovery of ALP specific
activity.

2. IS PROTEIN SYNTHESIS REQUIRED FOR THE ZINC-DEPENDENT
REVERSAL?
To determine whether the effect of zinc to reverse the loss of cell layer ALP specific
activity that follows phosphate withdrawal requires protein synthesis, replicate cultures of
SaOS-2 cells (n=6) were preincubated for 48 hours in 0 Pi media to reduce ALP specific
activity and then incubated for 24 hours with 3 [H]-proline, in the presence and absence of
3 pmol/L cycloheximide (a protein synthesis inhibitor) in one of four treatment media
(1.8 mmol/L Pi, 0 Pi, 0 Pi + lOpmol/L Zn, or 1.8 mmol/L Pi + 10 pmol/L Zn). Parallel
cultures treated at the same zinc and phosphate doses with and without cycloheximide but
without [H]-proline were also prepared for measurement of ALP specific activity.
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Figure 14 shows the incorporation of 3 [H]-proline, expressed as counts per minute (cpm),
into newly synthesized protein. These results indicate that the treatment with
cycloheximide effectively inhibited new protein synthesis in all the treatment groups.
Figure 15 shows the parallel effects of these incubations on ALP specific activity. As in
previous experiments, we found that, in the absence of cycloheximide, phosphate and
zinc alone and in combination reversed the loss of ALP specific activity that follows
phosphate withdrawal. In the presence of cycloheximide, however, only partial recovery
of ALP specific activity was observed in the extracts of cells treated with zinc, alone or
with phosphate and no recovery was observed in the extracts of cell treated with
phosphate alone.

3. DOSE-DEPENDENT EFFECTS OF ZINC ON THE RELEASE OF ALP
ACTIVITY INTO THE CULTURE MEDIUM
The observed effect of zinc to increase the cellular level of ALP activity could be due
to inhibition of the release of enzyme from the cell membrane into the culture medium.
To test this hypothesis, SaOS-2 cells were exposed to phosphate-free media containing
one of seven doses of zinc (0, 0.2, 0.5, 1.0, 2.0, 5.0 and 10 pmol/L). Following 28 hours
of incubation in these effector media, the cell-conditioned media were collected and the
cell layers were extracted with triton X-100. ALP activity was measured in the
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Figure 14. Effect of Cycloheximide on Protein Synthesis. Protein synthesis was inhibited by cycloheximide, independent
of zinc (Zn) and phosphate (Pi) concentrations. Replicate cultures (n=6) were preincubated 48 hours in serum-free, phosphatefree BGJb medium, then incubated an additional 24 hours in serum-free BGJb medium +/- 3 pmol/L cycloheximide and
1.8 mmol/L Pi, 0 Pi, 0 Pi + 10 pmol/L Zn, or 1.8 mmol/L Pi + 10 pmol/L Zn. Protein synthesis was measured by
incorporation of [3H]-proline into newly synthesized protein during the final 16-hours of incubation in serum-free, low proline
BGJb (1% of normal proline) with 50 ug/mL BAPN and 50 ug/mL ascorbate and is expressed as cpm/well. All values are
expressed as mean ± SEM. * Difference from corresponding 0 cycloheximide controls, p < 0.001.
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Figure 15. Protein Synthesis is Required for Full Recovery of ALP. Protein synthesis was required for the full recovery of
ALP specific activity after loss due to phosphate withdrawal. Replicate cultures (n=6) were preincubated 48 hours in
serum-free, phosphate-free BGJb medium, then incubated an additional 24 hours in serum-free BGJb medium containing
+/- 3 pmol/L cycloheximide and 1.8 mmol/L phosphate (Pi), 0 Pi, 0 Pi + 10 pmol/L zinc (Zn), or 1.8 mmol/L Pi +
10 pmol/L Zn. ALP specific activity was measured as U/mg protein and is expressed as mean ± SEM. * Difference from
0 mmol/L Pi, 0 hour controls, p < 0.001.
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cell-conditioned media and cell layer extracts, and the protein concentrations of the cell
layer extracts were determined. Table 3 shows the results of our assays of ALP specific
activity in the cell layer extracts and in the cell-conditioned media each expressed in
absolute terms and as a percent of control (0 Zn-treated cells). As in previous studies,
ALP specific activity of the cell layer extracts showed a dose-dependent increase with
zinc with a maximal effect of about 360 - 390% of control. The ALP specific activity of
the cell-conditioned media showed an even greater increase in response to zinc with a
maximal effect of 750% of control at the highest zinc dose. These data suggest that zinc
is not increasing ALP specific activity by decreasing the release of ALP from the
membrane.

4. EFFECT OF ZINC ON ALP mRNA
To determine if the increased ALP specific activity levels found in cells incubated
with zinc and phosphate was associated with an increase in ALP mRNA levels, we
performed Northern blot analysis on extracts of SaOS-2 cell cultures which had been
incubated for 48 hours in one of the following four treatment media: (a) phosphate-free
medium, (b) 1.8 mmol/L Pi, (c) 10 pmol/L Zn and (d) 1.8 mmol/L Pi + 10 pmol/L Zn.
Replicate (n=3) total RNA isolates from each treatment conditions were each separated
on duplicate agarose gels and transferred to nylon filters. The blots were probed for ALP
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Table 3. Effect of Zinc on the Release of ALP Activity. ALP specific activity in SaOS-2 cell extracts and on
cell-conditioned media was increased by zinc (Zn). Replicate cultures (11=6) were incubated 28 hours in serum-free BGJb
medium containing 0-10 pmol/L Zn. Cell layer ALP specific activity (Mean Cell ALP SA) and cell-conditioned medium
ALP specific activity (Mean CM ALP SA) was measured as U/mg protein and are expressed as mean ± SEM and percent of
control. *Difference from 0 zinc controls, p < 0.001.

(SEM)

%of
Control

Mean CM
ALP SA

(SEM)

%of
Control

1.57

0.04

100

0.028

0.004

100

0.2

2.50

0.06

159*

0.078

0.008

278*

0.5

3.20

0.25

204*

0.129

0.013

461*

1.0

3.41

0.23

217*

0.172

0.021

614*

2.0

4.18

0.14

266*

0168

0.011

600*

5.0

4.53

0.33

290*

0.186

0.010

664*

10.0

4276

0.20

266*

0.211

0.032

754*

[Zinc] |imol/L

Mean Cell ALP
SA

0.0

VO
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and actin mRNA using radioactively-labeled ALP and (3-actin cDNA’s, and
autoradiography was performed. Figure 16 depicts the autoradiographs of representative
portions of one blot after hybridization with the ALP probe (upper autoradiograph) and
the [3-actin probe (lower autoradiograph). ALP mRNA levels, measured by laser
densitometric determinations of area under the peak of the ALP bands of the
autoradiograph, were normalized to [3-actin mRNA levels to correct for loading variation
between lanes of the gel. The normalized band densities from of each of the duplicate
gels was averaged for each RNA sample and the mean density of the three replicate ALP
mRNA extracts was calculated for each treatment. Analysis of variance comparisons of
the treatment averages showed no significant differences between treatment groups.
Next, the averages were used to estimate the relative ALP mRNA level (the average band
density of each treatment group divided by the average band density of the 1.8 mmol/L Pi
control group). These relative ALP mRNA levels are depicted in the lower panel of
Figure 16. The nylon filters were also stained with methylene blue dye in order to
visualize the 18S and 28S ribosomal bands and the density of these ribosomal bands was
quantified using the laser densitometer. The ALP mRNA levels were also normalized to
the values obtained by laser densitometry for the 18S and 28S ribosomal bands of the
blots. As before, analysis of variance comparisons of the ALP data showed no significant
differences between treatment groups, whether the values were normalized to 18S level,
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Figure 16. Effects of Zinc and Phosphate on ALP mRNA. Autoradiographs of
Northern blot analysis and quantitation of the effect of zinc (Zn) and phosphate (Pi) on
ALP mRNA levels in SaOS-2 cells. ALP mRNA levels were not effected by zinc or
phosphate (alone or in combination). Replicate cultures (n=3) in 100-mm dishes were
incubated 48 hours in serum-free BGJb medium containing 1.8 mmol/L Pf 0 Pi,
0 Pi + 10 pmol/L Zn, or 1.8 mmol/L Pi + 10 pmol/L Zn were pooled and total RNA was
extracted. Replicate (n=3) total RNA isolates from each treatment group were separated
on duplicate gels and probed for ALP (upper blot) and p-actin mRNAs (lower blot) using
radioactively-labeled ALP and p-actin cDNA’s. Quantitation of band densities (graph at
bottom) was determined by laser densitometric scans. ALP mRNA average band densities
of duplicate blots were normalized to corresponding p-actin bands. Means ± SEM of
replicate RNA isolates (n=3) were calculated and are expressed as relative ALP mRNA
levels compared to 1.8 mmol/L Pi control.
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28S level or the sum of 18S and 28S levels (data not shown). The zinc dependent
increase in ALP specific activity was not associated with a proportional increase in ALP
mRNA. Zinc does not increase the level of ALP in SaOS-2 cells by increasing ALP
gene transcription and/or mRNA stability.

5. DOSE-DEPENDENT EFFECTS OF ZINC ON ALP IMMUNOREACTIVE
PROTEIN
The immunoreactive ALP protein of cell extracts from SaOS-2 cultures incubated for
28 hours in phosphate-free BGJb media with one of seven zinc doses was measured using
a two-site immunoradiometric assay (a commercial kit). ALP immunoreactive protein
(ng/mL) was estimated from a curve generated by ALP standards provided in the kit. The
ALP specific activity of the cell extracts were also determined. Table 4 summarizes the
ALP specific activity and immunoreactive ALP protein in the cell layer extracts, each
expressed in absolute terms and as a percent of control (0 Zn-treated cells). Incubation
with increasing amounts of zinc resulted in the usual dose-dependent increase in ALP
specific activity. In contrast, the amount of ALP immunoreactive protein, as detected by
the two antibodies, was not significantly changed by treatment with zinc.
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Table 4. Effect of Zinc on ALP Immunoreactive Protein. ALP specific activity in SaOS-2 cells is increased by zinc (Zn)
but ALP immunoreactive protein is not. Replicate cultures (n=6) were incubated 28 hours in serum-free BGJb medium
containing 0-10 pmol/L Zn. Cell layer ALP specific activity (Mean Cell ALP SA) was measured as U/mg protein. ALP
immunoreactive protein (Mean ALP Immun. Prot.) was measured by two-site immunoradiometric assay kit and is expressed in
ng/mg protein. All values are calculated as mean ± SEM and are expressed as percent of control. * Difference from 0 zinc
controls, p < 0.001.

(SEM)

% of
Control

Mean ALP
Immun. Prot.

(SEM)

%of
Control

1.57

0.04

100

0.535

0.03

100

0.2

2.50

0.06

159*

0.478

0.03

89

0.5

3.20

0.25

204*

0.453

0.03

85

1.0

3.41

0.23

217*

0.444

0.05

83

2.0

4.18

0.14

266*

0.488

0.02

91

5.0

4.53

0.33

290*

0.507

0.03

95

10.0

4276

0.20

266*

0.525

0.02
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6. EFFECTS OF CHELATION WITH EDTA ON ALP SPECIFIC ACTIVITY IN
THE PRESENCE AND ABSENCE OF PHOSPHATE
To test the hypothesis that phosphate may act to regulate ALP activity by preventing
the dissociation of the enzyme’s intrinsic zinc atoms, cells were incubated for 17 hours at
one of three concentrations of ethylenediaminetetraacetic acid (EDTA) (0, 5, and
10 pmol/L) over a wide range of phosphate concentration (0, 0.167, 0.20, 0.25, 0.33,
0.50, 1.0, 1.5, 2.0, 5.0, and 10.0 mmol/L). At the end of the incubation, ALP specific
activity of the cell layer extract was determined and the results are summarized in
Figure 17. As in previous studies, ALP specific activity increased with increasing
phosphate concentrations. Furthermore, at each phosphate dose, treatment with EDTA
resulted in a dose dependent decrease in ALP specific activity. Lineweaver-Burke plots
(1/ALP specific activity vs 1/[P]) showed that EDTA acts as a non-competitive inhibitor
of the phosphate action on ALP specific activity. Phosphate increased ALP specific
activity to a level of 5.68 U/mg in the absence of EDTA, but only to 2.6 U/mg in the
presence of 3 pmol/L EDTA and 1.85 U/mg in the presence of 10 p,mol/L EDTA. These
changes in the estimated maximal effect of phosphate on ALP specific activity were not
accompanied by changes in the Km value (concentration of phosphate required to yield
50% of maximal effect). The estimated Km value for phosphate in the absence of EDTA
was 0.30 mmol/L, and the estimated Km values for the 3 pmol/L and 10 pmol/L EDTA
data were 0.41 mmol/L and 0.34 mmol/L, respectively.
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Figure 17. Kinetic Analysis: EDTA/Phosphate. Lineweaver-Burke reciprocal plot of the effect of
ethylenediaminetetraacetic acid (EDTA) on the phosphate-dependent changes in ALP specific activity in SaOS-2 cells.
Replicate cultures (n^h) were incubated 17 hours in serum-free BGJb medium containing 0 (circles), 3 (triangles), or
10 pmol/L (squares) EDTA over a range of phosphate (Pi) concentrations (0-10 mmol/L). ALP specific activity was
measured as U/mg protein and plotted as reciprocals of the means vs reciprocals of Pi concentration (mmol/L). Estimated Km
values (concentration of Pi required to yield 50% of maximal effect) as determined by reciprocals of x-axis intercept ranged
from 0.30 - 0.41 mmol/L Pi. Estimated maximal effects of phosphate on ALP specific activity were 5.68, 2.60 and 1.85 U/mg
for 1, 3 and 10 pmol/L EDTA, respectively.
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To further investigate the effects of EDTA and phosphate on ALP specific activity, the
ALP specific activity was determined in cells that had been exposed to a single dose of
EDTA (3 jamol/L) and one of four phosphate doses (0, 1.0, 3.0 or 10.0 mmol/L), at
several different time points (15 minutes, 30 minutes, 1, 2, 4, 7, 12 and 24 hours). As
seen in Figure 18, the EDTA caused a time-dependent decrease in ALP specific activity
at all four phosphate concentrations. However, the rate of decrease of ALP specific
activity was found to be dependent on phosphate concentration. A maximal decrease in
ALP specific activity was seen in the cells incubated in phosphate-free media. After
1 hour of incubation, in the presence of 1 mmol/L Pi, the observed decrease in ALP
specific activity was only 47% of the effect observed in the absence of phosphate.
Similarly, in cells treated with 3 mmol/L Pi and 10 mmol/L Pi, the EDTA was only 21%
and 7% as effective at decreasing ALP specific activity as it was in the absence of
phosphate. Results of treatment with 10 mmol/L Pi were similar to the results of the
3 mmol/L treatment and are omitted from Figure 18.

7. ARE INTACT LIVING CELLS REQUIRED FOR THE EFFECT OF ZINC ON
ALP SPECIFIC ACTIVITY?
To determine whether the effect of zinc on cell layer ALP specific activity requires
intact living cells, we examined the effect of zinc on ALP activity in the absence of living
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Figure 18. Effect of Phosphate on the Inhibition of ALP by EDTA. Time-dependent decreases in ALP specific activity in
the presence of the metal chelator, ethylenediaminetetraacetic acid (EDTA), are regulated by phosphate (Pi) in SaOS-2 cells.
Replicate cultures (n=6) were incubated in serum-free BGJb medium containing 0 (circles), 1 mmol/L (triangles), or
3 mmol/L (squares) Pi over 24 hours as indicated. ALP specific activity was measured as U/mg protein and is expressed as
mean ± SEM. * Difference from 0 hour control, p < 0.001.
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cells. Five mL of four day serum-free cell-conditioned medium (containing ALP activity
that had been released from the cell) were collected from a 100-mm diameter dish and
centrifuged to remove cell debris. The ALP-containing cell-conditioned medium was
divided into 8 aliquots which were then diluted 1: 20 in one of four treatment media
(1.8 mmol/L Pi, 0 Pi, 0 Pi + 10|umol/L Zn, or 1.8 mmol/L Pi + 10 jamol/L Zn). One set
of the four diluted media were incubated at ambient room temperature (22°C) and the
second set of four diluted media were incubated at 4°C. Both sets were incubated for a
total of 53 hours. Aliquots were removed and assayed for ALP activity at 2, 6, 12, 27 and
53 hours. To reduce interassay variation, a single p-nitrophenylphosphate substrate
solution was prepared, divided into aliquots and stored at -20°C for use in all of the
assays. Data for the cell-conditioned media incubated at room temperature are
summarized in Figure 19. ALP activity decreased to a greater extent in the 0 Pi medium
than in the media containing zinc. The most marked drop in ALP activity occurred in the
0 Pi-diluted cell-conditioned media (53% remaining activity after 53 hours). The other
three treatment groups showed similar values of remaining activity: 74% for the
1.8 mmol/L Pi group, 79% for the 0 Pi + 10 pmol/L Zn group and 76% for the Pi/Zn
combination group. Results of the Pi/Zn combination treatment were very similar to the
0 Pi + 10 pmol/L Zn group and, therefore, are not shown in Figure 19. Results of the
groups incubated at 4°C were similar to the groups incubated at room temperature,

o

4-*

Figure 19. Zinc and Phosphate Slow the Loss of ALP Activity in the Absence of Cells. Time-dependent decreases in cellfree ALP specific activity from SaOS-2 cells were prevented by phosphate (Pi) and zinc (Zn). Five mL of four day serum-free
BGJb cell-conditioned medium was divided into aliquots which were diluted (1:20) in one of four treatments: 1.8 mmol/L Pi,
0 Pi, 0 Pi + 10 pmol/L Zn, or 1.8 mmol/L Pi + 10 pmol/L Zn and incubated at room temperature for 53 hours. Aliquots at 2,
6, 12, 27, and 53 hours were removed and ALP specific activities were measured as U/mg protein and are expressed as mean ±
SEM. * Difference from 0 mmol/L Pi, 0 hour controls, p < 0.001.
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however, there was a smaller decrease in ALP activity over the 53 hours of incubation
(data not shown). Together, these data suggest that phosphate and zinc alone and in
combination are able to slow the rate of the decrease of ALP specific activity that occurs
in the absence of phosphate, and that the ability of zinc to maintain levels of ALP activity
are, at least in part, due to a process which does not require living cells.

8. EFFECTS OF ZINC ON THE HALF-LIFE OF ALP ACTIVITY
To determine if the effect of zinc to increase ALP activity was due to increases in the
stability of the ALP enzyme, replicate cell cultures (n=6) were incubated in one of the
following four treatment medium: (a) 0 Pi, (b) 1.8 mmol/L Pi, (c) 10 jumol/L Zn and
(d) the combination of phosphate and zinc.

The incubations were stopped at several

time points (0, 2, 4, 6, 12, 24, and 30 hours) and the ALP specific activity of the cell
extracts were measured. Cycloheximide (3 pmol/L) was included in all the culture media
to prevent the addition of new ALP protein to the cells. In this way, loss of the ALP
activity present at the beginning of the incubation could be followed over time. As
shown in Figure 20, the ALP specific activity of the extracts of cells incubated in
phosphate-free media showed a rapid decrease in ALP activity over time, with the
half-life of ALP (i.e. the amount of time required for loss of half of the enzyme activity)
of approximately 3 hours. Incubation with 1.8 mmol/L Pi resulted in a less dramatic
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Figure 20. Zinc and Phosphate Slow the Loss of ALP Activity in Cells. Time-dependent decreases in ALP specific activity
in the presence of a protein inhibitor (cycloheximide) are prevented by phosphate (Pi) and zinc (Zn) in SaOS-2 cells. Replicate
cultures (n=6) incubated 30 hours serum-free BGJb medium containing 3 pmol/L cycloheximide and 1.8 mmol/L Pi (squares),
0 Pi (circles), 0 Pi + 10 pmol/L Zn (triangles), or 1.8 mmol/L Pi + 10 pmol/L Zn (diamonds). ALP specific activity was
measured as U/mg protein and is expressed as mean ± SEM. * Difference from 0 hour controls, p < 0.001.
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loss of ALP activity, with a half-life estimated to be 30 hours. Extracts of cells incubated
with zinc alone or in combination with phosphate showed no loss of ALP specific activity
over the 30 hours of incubation. Because the inhibition of protein synthesis (caused by
the presence of cycloheximide) results in cell death at incubations over 30 hours, we
could not determine the half-life of the ALP in the presence of zinc alone or in
combination using this method.

9. WILL ZINC INCREASE THE STABILITY OF PURIFIED ALP?
To determine whether the effect of zinc on ALP activity reflects a direct effect on the
skeletal ALP protein or an indirect effect which is also dependent on other cofactors, we
compared the effects of phosphate and zinc on the activity of purified skeletal ALP and a
crude preparation of the enzyme. A crude preparation of skeletal ALP was obtained as
48 hour cell-conditioned medium from confluent, serum-free cultures of SaOS-2 cells.
Nearly all of the ALP in the preparation was insoluble, in the form of membrane vesicles.
An aliquot of this material was reserved for use as an unpurified enzyme control. The
remaining volume of the cell-conditioned medium was used as a source of enzyme for
purification. Soluble ALP was released from the membrane vesicles by incubation with
phospholipase C and partially purified by concanavalin A column chromatography and
gel filtration chromatography. Table 5 summarizes our partial purification of ALP.
Although the treatment with phospholipase C did not result in a significant increase in

o

Table 5. Purification of Skeletal ALP. Partial purification of skeletal ALP from cell-conditioned medium from SaOS-2
cells. The crude enzyme preparation which was obtained as 48-hour cell-conditioned media, was incubated 48 hours with
1000 units phopholipase C (B. cereus) at 4 °C with constant stirring (to convert ALP to its anchor-less, soluble form) and
subjected to affinity chromatography (concanavalin A) and gel filtration chromatography (Sepharose CL - 6B200).
Purification was determined by comparison of ALP specific activity following each purification step and ALP specific activity
of the crude extract. Recovery of each purification step was determined as percent of total ALP activity (volume x ALP
activity) of crude extract.

Volume
(mL)

[Protein]
(mg/mL)

ALP Act
(U/mL)

ALP Spec.
Act (U/mg)

Purification
(-fold)

Recovery

Crude extract

500

0.20

0.22

1.10

1

100

PLC concentrate

32

1.64

1.83

1.12

1.01

53

Concanavalin A
peak

3.2

0.98

10.10

10.31

9.37

29

Sepharose peak

16.2

0.15

2.2

14.67

13.33

32

Purification
Preparation

(%)

M
t-1
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enzyme purity, and only allowed the recovery of approximately 53% of the ALP activity,
it resulted in the conversion of insoluble (GPI-anchor-intact) to an anchorless, soluble
form. Application to the concanavalin A column procedure resulted in a 9.3-fold increase
in ALP purity, while resulting in 29% recovery of activity. Application to the sepharose
column resulted in only a small increase in purity (up to 13.33-fold) with no significant
loss of total ALP activity.
Replicate aliquots of the crude extract and the partially purified skeletal ALP were
incubated in calcium-free media: (a) without phosphate, (b) with phosphate, (c) with zinc
and (d) with phosphate and zinc at 22°C for 24, 48 and 72 hours. As seen in Figure 21,
ALP activity was decreased with time in the absence of phosphate, and this effect was
(at least, partly) prevented by phosphate and zinc. Since similar results were seen with
the crude ALP preparation and the partially purified enzyme, these studies suggest that
the effect of phosphate withdrawal and the protective effect of zinc represent direct
effects on the skeletal ALP protein.

CO

Figure 21. Zinc and Phosphate Slow the Loss of Activity in Partially Purified ALP. Time-dependent decreases in ALP
specific activity of partially purified cell-conditioned media of SaOS-2 cells were prevented by phosphate (Pi) and zinc (Zn).
Partially purified ALP enzyme preparation was divided into aliquots which were diluted (1:20) in one of four treatments:
1.8 mmol/L Pi, 0 Pi or 0 Pi + 10 pmol/L Zn and incubated at room temperature for 72 hours. Aliquots diluted similarly in
1.8 mmol/L Pi + 10 pmol/L Zn gave results similar to aliquots diluted in 10 pmol/L zinc (data not shown). Aliquots at
0, 24, 48, and 72 hours were removed and ALP specific activities were measured as mlJ/mg protein and are expressed as
mean ± SEM. * Difference from 0 mmol/L Pi, 0 hour controls, p < 0.001.
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C. SPECIFIC AIM HI - To determine whether the observed effects of zinc are
physiologically relevant, by testing the effect of zinc on skeletal ALP activity in the
serum and the bones of adult female mice.

1. DOSE-DEPENDENT EFFECTS OF ZINC ON ALP SPECIFIC ACTIVITY IN
THE PRESENCE OF BOVINE SERUM ALBUMIN
Because the majority of zinc in serum is protein-bound, the influence of albumin on
the dose-dependence of the zinc effect was assessed (data not shown). Replicate cultures
of SaOS-2 cells (n=6) were incubated for 48 hours with one of ten different doses of zinc
(0, 0.1, 0.2, 0.5, 1.0, 2.0, 5.0, 10.0, 20.0 and 50.0 pmol/L) with or without 10 mg/mL of
albumin (BSA) in the absence of phosphate. The dose-dependent effects of zinc were
similar to the effects summarized in Figure 3 for the cells grown without phosphate
(i.e. a hyperbolic relationship between ALP specific activity and log [Zn] was observed).
Although the presence of albumin decreased basal (0 Zn) levels of ALP activity, zinc still
caused dose-dependent increases. Furthermore, the estimated Km value for zinc in the
albumin-treated cells was comparable (0.75 pmol/L) to that observed in the absence of
albumin (1.0 pmol/L). Together these data suggest that the dose dependent effect of zinc
to increase ALP specific activity is not dependent on ionic free zinc. The decrease in
basal ALP activity seen in the presence of albumin was associated with an increase in
total protein in the cell layers of the albumin-treated cells. We hypothesize that albumin
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enhanced proliferation of the cells, resulting in a larger number of less well-differentiated
cells in these culture media, and ALP expression is believed to be a function of mature
osteoblasts.

2. DOSE-DEPENDENT EFFECTS OF ZINC ON ALP ACTIVITY IN MICE
As a means of determining the physiological relevance of the in vitro actions of zinc
on ALP activity, we tested the effect of zinc deficiency and zinc supplementation on the
observed ALP levels in the serum and bones of mice. Following random assignment to
treatment groups, the initial total body weights for each mouse were determined. One of
five dietary treatments were applied to each group for four weeks or six weeks:
a zinc-deficient diet, a normal diet, a normal diet supplemented (with zinc acetate in the
drinking water) to yield a total zinc intake of approximately 2x that provided by the
normal diet, a normal diet supplemented to yield a total zinc intake of approximately
3x the normal diet, and a normal diet supplemented to yield a total zinc intake of
approximately 4x the normal diet. At the end of four weeks and six weeks of treatment,
final total body weights were measured and the groups of mice were euthanized (under
ethrane anesthesia). There were no significant differences in total body weight gain
between the treatment groups indicating that the various treatments did not alter the
eating habits or nutrient conversion efficiencies of the mice (data not shown). Blood
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samples were collected and, following centrifugation, the ALP activities of the sera were
measured. Calvaria and tibia were dissected and extracted with triton and the ALP
activities of the bone extracts were measured. The bones were briefly incubated in
ethanol, dried overnight and the dry weights of the bones were determined. ALP activity
values of the bone extracts were normalized to bone weight by dividing the ALP activity
(U/mL) by the dry bone weight (mg).
Figure 22 shows the plot of mean serum ALP activity against relative level of zinc in
the diet for the six week mice. A positive correlation between serum ALP activity
(primarily skeletal ALP) and relative zinc content of the diet was observed. In these same
mice, a similar relationship was observed between the ALP activity extracted from the
tibia normalized to bone dry weight and the dose of zinc (Figure 23). In each case, the
correlations were significant with correlation coefficients of 0.965, p < .01 for serum
ALP and r = 0.898, p < .05 for tibia ALP/bone dry weight. In the four week-treated mice,
the plots of serum ALP activity and tibial ALP/bone dry weight vs relative zinc in the
diet also showed significant positive associations (r = 0.596, p < .001 and r = 0.397,
p < .02, respectively). In contrast, analysis of the ALP levels in the calvaria bone
extracts, of both the four week and the six week mice, showed no significant association
with the zinc content of diet.

I-1
h-1

oo

Figure 22. Effect of Dietary Zinc on Serum ALP Activity in Mice. Serum ALP activity is positively associated with the
relative amount of zinc (Zn) in the diet of adult, female mice. Randomly assigned groups of mice were treated with one of the
following five diets for six weeks: 0 = Zn-deficient diet, 1= normal diet, 2 = 2x normal diet, 3 = 3x normal diet and 4 = 4x
normal diet. Sera from blood samples were collected and ALP activities were measured as U/mL Data shown are mean values
± SEM for each dietary group of 8 mice (r = 0.97, p < 0.001).
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Figure 23. Effect of Dietary Zinc on Tibial ALP Activity in Mice. Tibial ALP specific activity normalized to dry bone
weight is positively associated with the relative amount of zinc (Zn) in the diet of adult, female mice. Randomly assigned
groups of mice were treated with one of the following five diets six weeks: 0 = Zn-deficient diet, 1= normal diet,
2 = 2x normal diet, 3 = 3x normal diet and 4 = 4x normal diet. Tibia were dissected, ALP specific activities of the tibial bone
extracts were measured as U/mg and were normalized to the corresponding dry bone weights and are expressed as
mean ± SEM for each dietary group of 7 - 13 mice (r = 0.898, p < 0.05).
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DISCUSSION

Zinc is known to be essential for the normal growth of animals (15"20) and humans/9’1
Although numerous metabolic functions have been characterized which appear to require
zinc, very little is known about the biochemical mechanisms by which zinc influences
growth. Because zinc is concentrated in bone compared to the rest of the body (only
skeletal muscle tissue contains more zinc than bone) ' and because zinc appears to be
concentrated in the hypertrophic zone of epiphyseal cartilage (25,26) (the area of new bone
growth) the effect of zinc on normal growth is probably mediated by or, at least
associated with, its effect on bone formation. The majority of the studies investigating
the effect of zinc on bone formation and skeletal metabolism have been done in the rat
model. Previous studies of skeletal tissue from rodents have demonstrated the ability of
(27,34)
(27,31)
bone mineralization,
zinc to increase DNA content, (27-30) collagen production

protein synthesis,

(29,30,43)

and ALP activity.

(27,31,38,42)

Previous studies have also

suggested that zinc may inhibit bone resorption in rats by reducing osteoclastic activity
and/or osteoclast formation.

(32)

(33\

We focused our attention on the effect of zinc on skeletal ALP activity because ALP is
considered to be a zinc-containing metalloenzyme(58) and is also considered to be
important in bone formation. We performed most of our studies on the human
osteosarcoma cell line, SaOS-2, because it contains high levels of human skeletal ALP
activity. Previous studies in these cells have suggested that phosphate and
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phosphate-ester analogues can regulate the level of ALP activity, such that the amount of
ALP activity is directly proportional to the phosphate (or analogue) concentration in the
medium/63,65) Recently, we have observed that low levels of zinc can also increase ALP
specific activity. Current studies were designed to investigate the effects of zinc on
skeletal alkaline phosphatase. To achieve this, we undertook the following three goals:
(1) Characterize the effect of zinc on ALP under various experimental conditions in a
human osteoblast-like cell model; (2) Investigate the mechanisms by which zinc
increases ALP specific activity in the same cell model; and (3) Determine if the effect of
zinc on ALP specific activity is physiologically relevant. Although previous studies have
reported effects of zinc on skeletal tissue, this study is the first to undertake an in-depth
characterization of the effect of zinc on skeletal ALP activity in a human bone cell model.
For the bone cell model, we selected SaOS-2 cells, a human osteosarcoma cell line,
because of the high basal levels of ALP activity expressed in these cells. Furthermore,
the ALP activity of these cells has been shown to be similar to the skeletal alkaline
phosphatase activity in human serum(62) and, as an osteosarcoma-derived cell line, the
cells are easily maintained in culture.
Exposing SaOS-2 cells to a wide range of zinc doses resulted in a dose-dependent
increase in ALP specific activities of the cellular extracts. The maximal effect of zinc on
ALP specific activity was between 2 and 50 pmol/L zinc, while doses above 100 pmol/L
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were toxic. The effect of zinc to increase ALP specific activity was also observed to be
time dependent. Measurements taken during a 72 hour period showed ALP activity
increased in cells incubated in the presence of zinc alone or in combination with
phosphate with significant increases occurring with incubations over 24 hours.
Plating cells at various initial cell densities revealed a biphasic relationship between
ALP specific activity in the absence of supplemental zinc. However, the previously
characterized effects of zinc and phosphate on ALP specific activities were observed over
the entire range of initial cell densities tested. From these data, we conclude that the zinc
effect to increase ALP activity was not dependent on the density of the cell culture.
Our studies indicate that the effect of zinc to increase ALP activity in osteosarcoma
cells is relatively unique to zinc, in that, incubation with other divalent cations (calcium,
cobalt, copper, iron, magnesium, and manganese) under the same conditions, was not
associated with increases in ALP specific activity and, in fact, were associated with
significant decreases. These findings are consistent with previous studies which showed
that the ALP activity of the femoral diaphyses of weanling rats, was increased in response
to zinc, but treatment with comparable doses of copper, magnesium, cobalt, nickel, and
chromium III resulted in significant decreases in ALP activity. (28) The zinc-dependent
increases in ALP activity were not unique to the SaOS-2 cell line. Increases in ALP
specific activity were also observed in three other cell lines; two normal human bone cell
lines and the osteosarcoma cell line MG-63. Although basal levels of ALP specific
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activity varied widely between the three cell lines and the SaOS-2 cells, the relative
increases in ALP activity of the zinc-treated cells (reported as percent of control) were
similar in the four cell lines. Since two of the four cell lines were normal human bone
cell lines, these data suggest that our bone model system (SaOS-2 cells) is comparable to
that of normal bone cells, with respect to the effect of zinc on ALP activity.
To determine if the effect of zinc on ALP activity would be associated with
proportional changes in other osteoblastic characteristics, we examined the effect of zinc
on the following three indices of osteoblastic differentiation: collagen synthesis, net
IGF-II synthesis and PTH-dependent cAMP production. Previous studies

(57)

of

subpopulations of SaOS-2 cells, which differ in their ALP specific activity levels,
showed that the amount of collagen synthesis measured as collagenase-digestible protein
released is proportional to the ALP specific activity, suggesting that subpopulations with
high levels of ALP are more osteoblastic than those with low levels of ALP.
PTH-dependent cAMP production in the subpopulations of SaOS-2 cells was also
proportional to ALP activity. These data suggest the possibility that zinc indirectly
causes ALP activity to increase by inducing osteoblastic differentiation, as has been
observed with bone formation stimulating agents such as fluoride and calcitonin. (66)

If

this were the case, we would predict that zinc-dependent increases in collagen synthesis
and PTH-dependent cAMP would be observed. However, it is also possible that zinc
directly effects ALP activity, with no accompanying effects on other differentiation
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markers. Since we observed no effect of zinc on the production of collagen and a small
effect of zinc on PTH-dependent cAMP synthesis (which was not proportional to the
effect on ALP activity), our data support the latter hypothesis that zinc is acting directly
on ALP, not on differentiation.
Our results also showed that incubation with increasing zinc doses inversely affected
the IGF-II levels in the cell-conditioned, calcium free medium. Net IGF-II production
decreased as a function of zinc concentration in the incubation media. These data are
consistent with previous findings that the net synthesis of IGF-2 by human bone cell
cultures was inversely associated with the cellular ALP level,

but the effects of zinc to

decrease IGF-2 net synthesis were much smaller than the effect to increase ALP activity.
To further characterize the effect of zinc in our osteosarcoma cell model, we examined
the effect of zinc on several cellular classes of acid phosphatase (AcP) activity
(total AcP, tartrate resistant AcP, and fluoride-sensitive AcP). To determine if the effects
of zinc on AcP activities, we measured the specific activities of total AcP,
tartrate-resistant, fluoride-sensitive AcP, and ALP (as a positive control for the effect of
zinc) in extracts of replicate cultures of cells that had been incubated with a range of
doses of zinc. Positive correlations between zinc and total AcP and between zinc and
ALP were found. No correlation was observed between zinc and TRAP specific activity
nor between zinc and fluoride-sensitive AcP activity. Together, these data demonstrate
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that the effect of zinc on human osteosarcoma cells is not unique to ALP, but could also
be observed with another phosphatase enzyme. It should, however, be noted that the
magnitude of the effect of zinc on ALP was significantly greater than the effect of zinc on
tartrate-resistant AcP. An analysis of the biochemical and/or physiological significance
of the effect of zinc on total AcP activity was beyond the scope of our investigations and
will require further study.
Previous studies have shown that phosphate could regulate the level of ALP activity in
SaOS-2 cells/63,64) Cell extract ALP specific activity decreases as the phosphate
concentration of the culture media is decreased. Our studies indicate that zinc and
phosphate, alone and in combination can reverse the loss of ALP activity which occurs in
cells incubated in phosphate-free medium. Our results also suggest that this reversal is
partially dependent on new protein synthesis, as evidenced by the fact that only partial
recovery of ALP specific activity was observed in extracts of cells incubated in the
presence of cycloheximide, a protein synthesis inhibitor. We can interpret these data to
mean that the loss of ALP activity which occurs with phosphate withdrawal is due, in
part, to an irreversible process and that the only way to achieve full recovery of ALP
activity is by the synthesis of new ALP protein. Additionally, the fact that some recovery
was achieved under these conditions (severe protein synthesis inhibition) suggests that a
process other than protein synthesis, such as an extension of the enzyme’s half-life, may
also be involved in this recovery process.
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The mechanisms by which enzyme regulators affect the measured activity of the
enzyme can be divided into two groups. The first group, which can be described as direct
effects, includes cases where the presence of a regulator causes an increase in the
enzyme’s affinity for substrate, an increase in the enzyme’s efficiency or an increase in
the stability of the enzyme. A second group of mechanisms by which a regulator can
affect an enzyme’s measured activity can be characterized as indirect effects. This
includes cases where the enzyme effector increases enzyme levels by increasing gene
transcription, mRNA stability/processing, or protein translation/processing. Enzyme
effectors can also increase enzyme activity indirectly by inhibiting the action of the
proteases responsible for the degradation of the given enzyme. Finally, with ectoenzymes
(such as ALP), another way to indirectly increase the level of enzyme activity in the cell
layer is by inhibiting the release of the enzyme from the membrane. One of the goals of
this project was to determine which of these various regulatory mechanisms is involved
in the effect of zinc on ALP activity. To accomplish this, we conducted several
experiments which were designed to test these various possible mechanisms of zinc
effects on ALP activity.
To start, we tested the hypothesis that zinc acts to increase ALP activity by inhibiting
the release of ALP from the cell membrane. ALP is an ectoenzyme attached to the cell
membrane via a glycan phosphatidylinositol anchor which can be cleaved by
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phospholipases C or D activity. 44) Inhibition of one of these phospholipases could result
in less ALP enzyme released into the culture medium and, therefore, an overall increase
in ALP activity in the cell layer. If the zinc-dependent increases in cellular ALP are due
to an inhibition of ALP release, we would expect to see proportionally less ALP activity
in the cell-conditioned media. Our data strongly contradict this hypothesis, in that, with
increasing zinc doses, we observed marked increases in the amounts of ALP specific
activity in both the cell layer and the cell-conditioned medium. It does not appear that
zinc increases cell layer levels of ALP activity by inhibiting the release of the enzyme
from the cell membrane.
Another explanation for the increase in ALP activity in cells treated with zinc is that
zinc may act to increase ALP mRNA levels, either by stabilizing ALP mRNA or
increasing transcription. It is possible that zinc treatment results in increased ALP
activity by enhancing the action of Spl. The promoter of the ALP gene has at least four
potential Spl-binding sites, (68, 69) and Spl is known to be a zinc-containing protein.

(70)

Therefore, it is possible that zinc enhances the action of Spl on the ALP promoter,
resulting in increased expression of ALP message and ALP protein. It is also possible
that the zinc-dependent increases are due to a positive effect of zinc on ALP mRNA
stability, in a manner similar to the effect of retinoic acid.(72) Finally, since the effect of
zinc on ALP activity appears to be similar to the effect of phosphate on ALP activity, we
wanted to determine whether zinc had a negative correlation with ALP mRNA similar to
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the negative association between phosphate and ALP mRNA levels. (64) To test the
specific hypothesis that the effect of zinc to increase ALP activity was due to increased
levels of ALP mRNA, Northern blot analysis was performed on total RNA extracts of
SaOS-2 cells incubated in one of the following four treatment media:
(a) phosphate-free medium, (b) 1.8 mmol/L Pi, (c) 10 pmol/L Zn and (d) 1.8 mmol/L Pi
and 10 pmol/L Zn. Replicate (n=3) preparations of total RNA were used for each gel in
our Northern blot analysis to allow for statistical analysis of the data. Analysis of
variance of the normalized ALP mRNA levels showed no significant differences between
the different treatment groups. From these data we concluded that zinc does not increase
the level of ALP activity in SaOS-2 cells by increasing the level of ALP mRNA. Another
study of ALP mRNA in SaOS-2 cells(64) demonstrated an inverse relationship between
the amount of phosphate in the incubation medium and the amount of ALP mRNA. We
found no such inverse effect of phosphate on ALP mRNA. One reason for the
discrepancy between these two results is that in the phosphate studies, high levels of
phosphate in the medium were achieved by using phosphate analogues and phosphate
esters. In our present study, we have limited ourselves to 2 mmol/L phosphate in the
culture medium because high levels of inorganic phosphate cause the spontaneous
formation of calcium phosphate crystals which disrupts the viability of the cell culture.
Therefore, we speculate that we did not achieve the high phosphate concentrations in the
medium which were shown in the previous study to decrease ALP mRNA levels.
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Zinc has been shown to increase ALP activity in femoral bone cultures of rats by
enhancing protein synthesis. (29,30,43) Therefore, we tested the hypothesis that zinc acted
to increase ALP activity in a similar manner in our cell model. To test this, we measured
the rate of protein synthesis (determined by the incorporation of radioactively-labeled
proline into new protein) of cells incubated over a range of zinc doses. Contradictory to
the results in the rat femoral bone cultures, our results showed no change in protein
synthesis with increasing doses of zinc. Total protein measurements of the cell layer
obtained using a protein-binding dye, also showed no effect of zinc on protein levels.
These results suggest that zinc does not act to increase ALP activity in our human
osteosarcoma cells by increasing the synthesis of skeletal ALP protein.
To test the more general hypothesis that zinc increases cellular ALP levels by
increasing the amount of ALP protein (i.e. by increasing ALP synthesis and/or increasing
the stability of skeletal ALP protein), cells were incubated over a range of zinc doses for
28 hours. Following the incubation, the ALP specific activity of the cell extracts were
measured and immunoreactive ALP protein was measured using a two-site
immunoradiometric assay kit. This assay uses a
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[ I ] radioactively-labeled monoclonal

antibody that recognizes one ALP epitope and a second, bead-linked monoclonal
antibody which is specific for a different ALP epitope. Recognition by both antibodies is
required for the detection of ALP protein; the bead-linked antibody is required for the
centripetal separation of the Ab-protein complexes from non-bound proteins, and the
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radioisotope-labeled antibody must be bound to the bead-Ab-protein complex for
radiometric quantitation. This technique is useful because the required recognition of two
different ALP epitopes, reduces the detection of non-ALP proteins and of ALP
degradation fragments due to cross-reactivity. The results of our studies showed the
expected increases in ALP specific activity levels in response to zinc, however, the
amount of ALP immunoreactive protein, as detected by the two antibodies, was not
significantly changed by treatment with zinc. The increase in cell layer specific activity
without an accompanying increase in ALP immunoreactive protein suggests that zinc is
not acting to increase the levels of ALP specific activity by increasing the amount of
enzyme on the cell surface, but rather that zinc is increasing the percentage of active
enzyme on the cell surface. In other words, the total amount of ALP enzyme on the
membrane is not increased by zinc but the amount of active enzyme is. Alternatively,
zinc may be acting to increase the enzymatic efficiency of the ALP already present on the
surface. The increase in the level of ALP activity in the cell-conditioned media without
an accompanying decrease in cell extract ALP immunoreactive protein is also consistent
with this hypothesis. That is, the zinc-dependent increase in ALP activity in the
cell-conditioned media is not a result of increased release from the cell membrane, but
rather, because zinc is acting to increase the percentage of active ALP present in the
cell- conditioned media.
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We, next, determined the half-life of ALP activity in SaOS-2 cells incubated in one of
the four standard treatment media (a) 0 Pi, (b) 1.8 mmol/L Pi, (c) 10 jnmol/L Zn and
(d) the combination of phosphate and zinc in the presence of the protein inhibitor,
cycloheximide. Cells incubated in phosphate-free media had a much shorter ALP
half-life than cells incubated with phosphate or zinc, alone or in combination. These data
suggest that zinc, like phosphate, can act to increase ALP activity by increasing the
stability of the enzyme.
Ethylenediaminetetraacetic acid (EDTA) is a metal chelator which has been shown to
inactivate ALP activity in E. coli}5^ swine kidney cells,(76) and human leukocytes. (77)
These enzyme inactivations are most likely caused by the dissociation of one or more
zinc atoms from the ALP enzyme. To test the general hypothesis that phosphate may act
to regulate ALP activity by preventing the dissociation of the enzyme’s intrinsic zinc
atoms, SaOS-2 cells were incubated at various concentrations of EDTA over a wide range
of phosphate concentrations. In the presence and absence of EDTA, ALP specific
activity increased in proportion to the phosphate concentration in the media. These
results confirm the finding of a previous studies

(63, 65)

which showed that phosphate

positively regulates ALP specific activity in SaOS-2 cells. Our data also showed that
EDTA caused a dose dependent decrease in ALP specific activity at every phosphate
dose, although phosphate modified the effect. Our kinetic analyses suggest that EDTA
acts as a non-competitive inhibitor of ALP specific activity, with respect to phosphate,
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because treatment with EDTA caused a change in the estimated maximal effect of
phosphate on ALP specific activity but did effect the estimated Km value
(the concentration of phosphate required to yield 50% of maximal effect). Therefore, we
conclude from these data that phosphate and EDTA do not appear to compete for the
same site on the enzyme.
The effects of EDTA and phosphate on ALP specific activity as a function of time
were then determined by incubating cells with a single dose of EDTA and a small range
of phosphate doses. A time-dependent decrease in ALP specific activity was observed at
all four phosphate concentrations. Furthermore, the rate of decrease of ALP specific
activity depended on the concentration of phosphate in the incubation medium. Cells
incubated in phosphate free-media showed the most dramatic decrease in ALP specific
activity in response to EDTA. Incubation with increasing doses of phosphate resulted in
proportionally higher levels of ALP specific activity despite the presence of EDTA,
suggesting that phosphate may regulate ALP activity by preventing the dissociation of
one or more metal ions (presumably, zinc) from the skeletal ALP enzyme.
To determine whether the effect of zinc on ALP activity was due to direct effects of
zinc on the enzyme or if the effect was dependent other cofactors (e.g. ALP proteolysis),
we examined the effect of zinc on ALP stability (in the absence of intact living cells) in
cell-conditioned media from SaOS-2 cell cultures, before and after partial purification.
Because the purification process was likely to remove any proteases present in the
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cell-conditioned medium, mechanisms acting indirectly to increase ALP activity, such as
inhibition of protease activity, would not be observed in a purified enzyme preparation.
In contrast, direct effects of a regulator (zinc) on an enzyme (ALP) should be apparent
even in the absence of intact living cells. Our results suggest that zinc has a direct effect
on ALP activity. The ALP specific activities of the crude cell-conditioned medium and
of the partially purified ALP preparation diluted in phosphate-free medium were
decreased with time to a greater extent than those diluted in media containing zinc and/or
phosphate. These data suggest that phosphate and zinc alone and in combination are able
to slow the rate of the decrease of ALP specific activity that occurs in the absence of
phosphate, and that the ability of zinc to maintain levels of ALP activity are, at least in
part, due to a direct effect on the enzyme which does not require living cells or other
co-factors. The rate of loss of ALP activity observed in the intact cells system was much
faster than that observed in the two cell-free systems (cell-conditioned medium and
partially purified enzyme preparations). This suggests that an ALP activity degradation
process is occurring in the intact cells that does not occur in the cell-free enzyme
preparations (i.e. cell-associated protease activity). The third goal of this project was to
determine if the observed effect of zinc on ALP activity is physiologically relevant. To
accomplish this, we first investigated the effect of albumin on the observed zinc effects
on ALP activity. In serum, the majority of the zinc is protein-bound (primarily to
albumin).(4) Therefore, if the effect of zinc on bone cell ALP activity is physiologically
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relevant, it is likely to be mediated by albumin-bound zinc, as well as free ionic zinc. We
found that although basal levels (0 zinc) of ALP activity were reduced in the presence of
albumin, the dose-dependent effect of zinc to increase ALP specific activity were still
observed. Furthermore, the dose of zinc required to achieve half of the maximal effect of
zinc on ALP specific activity in the presence of albumin was similar to the dose of zinc
required in the absence of albumin. Therefore, we hypothesize that the affinity of ALP
for zinc is greater than the affinity of albumin for zinc, thus supporting the possibility that
the observed effect of zinc on ALP activity is physiologically relevant.
To investigate the physiological significance of the effect of zinc on skeletal ALP
activity, the effect of dietary zinc levels on the ALP activity in the serum and the bones of
a small animal was determined. One of five dietary treatments were applied to one of
five groups of female adult mice for periods of four weeks and six weeks. The dietary
treatments ranged in zinc intake from a zinc deficient diet to a diet containing
approximately four times the amount of zinc found in the normal diet. Since no
significant difference in total body weight gain was observed between the treatment
groups, we concluded that treatment with the zinc deficient diet or zinc supplemented
diets did not effect the eating habits of the mice. Our results showed a positive
correlation between serum ALP activity (primarily skeletal ALP) and relative zinc
content of the diet in the mice treated for 4 weeks and 6 weeks. A similar relationship
was observed between the relative dietary dose of zinc and the ALP activity extracted
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from the tibia normalized to bone dry weight. In contrast, no significant association
between relative dietary zinc content and the ALP levels in the calvaria bone extracts was
observed in the four week nor in the six week mice. These results suggest that zinc can
act, in vivo, as it does in vitro, to increase the amount of skeletal ALP activity in bone and
in circulation.
In summary, our studies were intended to accomplish three specific aims. First, we
wanted to characterize the effects of zinc on skeletal ALP activity and on bone cell
metabolic processes. The results of our investigations showed that incubation with zinc
resulted in a time- and dose-dependent increase in the ALP specific activity, both in the
cell-conditioned media and in extracts of SaOS-2 cells. But a similar effect of zinc on
SaOS-2 cell layer total protein was not observed. The zinc-dependent increase in ALP
activity was not modified by cell density, although cell density did appear to effect basal
levels of ALP activity.
Extracts of cell incubated in phosphate-free media showed significantly lower ALP
specific activity than the extracts of cells incubated with phosphate. Zinc, however.
prevented the loss of ALP activity which resulted from phosphate withdrawal. This
ability of zinc to maintain and increase ALP activity in the absence of phosphate appears
to be unique to zinc, because incubation under identical conditions with any one of six
divalent metals other than zinc did not maintain or increase ALP activity. Furthermore,
our data showed that the effect of zinc to increase ALP specific activity was not unique to
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SaOS-2 cells. Two normal human vertebral cell lines and a human osteosarcoma cell line
other than SaOS-2, showed similar zinc-dependent increases in ALP activity.
The effect of zinc to increase ALP activity in SaOS-2 cells did not appear to be
associated with effects on protein synthesis. Furthermore, our studies showed that zinc
did not effect collagen production. Zinc did, however, have a biphasic dose-dependent
effect on PTH-dependent cAMP production. The magnitude of the change in the
production of PTH-dependent cAMP was small compared to the magnitude of the
zinc-dependent change in the ALP specific activity. This comparison demonstrates the
lack of proportional effects of zinc on ALP activity and these other indices of osteoblastic
differentiation (i.e. collagen synthesis and PTH-dependent cAMP synthesis) and suggests
that the effect of zinc to increase ALP specific activity is not an indirect effect that is
mediated by increases in bone cell differentiation. Instead, our data indicate that zinc
directly effects skeletal ALP activity without accompanying effects on other aspects of
differentiation.
Zinc also had a positive effect on tartrate-resistant acid phosphatase activity and a
negative effect on IGF-II synthesis in SaOS-2 cells. But like the effect on
PTH-dependent cAMP production, the zinc-dependent changes in IGF-II production in
response to zinc were small in comparison to the zinc dependent change in ALP activity.
Based on these data, we conclude that the mechanisms of action of zinc on these
osteoblastic processes are independent of the action of zinc on ALP activity.
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The second specific aim of this project was to determine the mechanism of action by
which zinc increases ALP activity in SaOS-2 cells. Incubation with zinc and/or
phosphate following preincubation in phosphate-free media resulted in only partial
recovery of the ALP activity which was lost by the phosphate withdrawal, and that new
protein synthesis is required for the full recovery of the ALP activity. These data suggest
that incubation in the absence of phosphate results in an irreversible loss of ALP activity.
It is possible the lack of phosphate in the media results in the permanent loss of ALP
activity by contributing to the irreversible inactivation of the ALP enzyme. On the other
hand, because some recovery of activity is obtained by incubation with zinc and/or
phosphate (even in the absence of new protein synthesis) we hypothesize that such
irreversible inactivation (i.e. caused by phosphate withdrawal) is not immediate in all the
ALP molecules.
Also, the effect of zinc to increase ALP activity in SaOS-2 cells was not associated
with changes in ALP mRNA levels, inhibition of the release of the enzyme from the cell
membrane or associated with changes in the amount of immunoreactive ALP protein. In
contrast, zinc increased the half-life of ALP activity in intact cells and in both purified
and crude ALP enzyme preparations, suggesting that zinc has a direct effect on the
stability of the ALP enzyme. Previous studies had, similarly, shown that the effect of
phosphate to regulate ALP activity may also result from direct effects of phosphate on the
ALP stability.
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In constructing a model of the mechanisms by which zinc and phosphate affect ALP
activity , we focused on the following three points. First, zinc must increase ALP activity
by directly acting on the enzyme. Second, the model must explain how most of the loss
of activity resulting from phosphate withdrawal is irreversible (and is only recovered by
the synthesis of new protein), yet some of the lost activity could be recovered by
incubation with zinc but not with phosphate. And third, the model must explain how
phosphate can protect the enzyme from the inactivating action of EDTA. In building our
model, we have also assumed that the cellular level of ALP activity is determined by a
balance between the processes of degradation and new protein synthesis. With these
points in mind, we constructed the following model to explain the results of our study.
We hypothesize that the two zinc atoms of the ALP enzyme have different
electrostatic forces acting upon them, based on their location in the active site of the
enzyme, such that, one zinc atom may dissociate from the ALP enzyme more easily than
the second atom (i.e. one of the zinc atoms is more tightly bound to the enzyme than the
other zinc atom). We further hypothesize that the dissociation of the loosely bound zinc
results in inactivation of the enzyme but that this inactivation is reversible (i.e. the
enzyme can readily reassociate with a zinc atom and restore enzymatic activity).
Dissociation of the tightly bound zinc, on the other hand, results in the irreversible
inactivation of the enzyme. Therefore, under normal conditions, phosphate binding to the
active center may slow the degradation of the enzyme by preventing the dissociation of
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the loosely bound zinc. In the absence of phosphate, and therefore without its protection,
the loosely bound zinc is more likely to dissociate from the ALP, inactivating the enzyme
in a reversible manner. With the loss of one zinc molecule, the structural conformation of
the ALP enzyme may slightly change in such a way that the probability of the
dissociation of the tightly bound zinc atom is increased. With the loss of the second zinc
atom, the structural integrity of the ALP enzyme may be permanently lost, resulting in
irreversible inactivation. With the addition of zinc to the medium following
preincubation in phosphate-free medium, zinc atoms would be able to reassociate with
ALP enzymes which have lost their loosely bound zinc and thus restore the enzymes’
catalytic activity. In contrast, the additional zinc could not reassociate with ALP
enzymes which have lost both zinc atoms. In that case, ALP activity
can only be recovered by new ALP synthesis. Furthermore, repletion of phosphate to the
medium following phosphate-free preincubation cannot replace the loosely bound zinc,
and therefore, activity is not recovered. Based on this model, we predict that phosphate
will inhibit the chelating action of EDTA and therefore, prevent the reversible
inactivation of the ALP enzyme by preventing the dissociation of the loosely bound zinc
atom from the enzyme. The results of our studies assessing the effect of incubation with
phosphate and EDTA are consistent with this model prediction.

142

The third and final aim of this project was to test the physiological relevance of the
effect of zinc to increase ALP activity. The effect of zinc to increase ALP activity in
SaOS-2 cells was not dependent on free ionic zinc, but also occurred with albumin-bound
zinc. Since the majority of zinc in the serum is bound to albumin, these observations
suggest that the zinc effect to increase ALP activity can occur in the natural physiological
environment. Furthermore, our mouse studies showed that dietary treatment with zinc
can effect the level of ALP activity in the serum and in the tibial bone extracts of adult
female mice. We conclude that the effect of zinc to increase ALP activity in human
osteosarcoma cells is physiologically relevant.
The results of the studies comparing the effects of zinc on ALP with the effect of zinc
on other osteoblastic differentiation markers, suggests that zinc may be used as a tool to
investigate the function of the ALP enzyme in SaOS-2 cells. Zinc influences the level of
ALP activity in the cells, directly, without causing comparable changes in osteoblastic
differentiation. Therefore, we speculate that in future studies zinc could be used as a
specific method to modulate the level of skeletal ALP activity in studies of possible ALP
function. Any changes in cell metabolism of a magnitude comparable to the changes in
ALP activity observed in the presence of zinc, could represent a consequence of ALP
activity. In this way, zinc may help us elucidate the physiological function of skeletal
ALP.
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The results of our studies also suggest an explanation for the protective effect of
phosphate on skeletal ALP activity. We can now hypothesize that phosphate increases
the half-life of skeletal ALP by binding to the enzyme near the catalytic site, thereby,
preventing the dissociation of one or both zinc molecules from the enzyme’s active
center. We can also hypothesize that one of the two molecules of zinc in skeletal ALP is
65

reversibly dissociable. Future studies, using purified skeletal ALP and Zn, in
equilibrium dialysis, will allow us to address that question (and to assess the effect of
phosphate on the process). Future studies will also allow us to answer the following
questions. Can phosphate, like zinc, regulate the level of skeletal ALP activity in serum
and in extracts of skeletal? Is skeletal ALP activity increased in the serum of human
subjects with higher serum levels (and/or dietary intakes) of either zinc or phosphate?
And finally, is the effect of zinc to increase skeletal ALP activity in vivo associated with
increases in osteoblast number or activity (i.e. metabolic activity or the extracellular
activities of bone formation and mineralization)?
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